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Arterial LDL deposition is a key step in initiating atherosclerosis. Saturated fat (SAT)-
enriched diets increase arterial LDL deposition, total and selective LDL-cholesterol uptakes, and 
arterial lipoprotein lipase (LpL). Because consumption of n-3 fatty acids (FA), such as EPA and 
DHA, potentially reduces the risk for cardiovascular disease (CVD), we investigated the 
mechanisms whereby dietary FA, metabolic syndrome and LpL interact to influence arterial lipid 
uptake in atherosclerosis. We hypothesized that specific FA, SAT versus n-3, alter the 
recruitment of different cell populations to the arterial wall and modulate arterial LpL levels and 
distribution, which in turn affects the development of atherosclerosis. 
To test these hypotheses, we carried out a series of dietary feeding studies in different 
mouse models to determine the effects of saturated versus n-3 FA on LDL-cholesterol delivery 
and arterial LpL levels. The data presented in this thesis demonstrate that high levels of saturated 
FA and insulin resistance contribute to accumulation of macrophages that secrete LpL and thus 
favor the development of atherosclerosis. Furthermore, deficiency of LpL in the arterial wall 
reduced aortic macrophage populations and macrophage infiltration. The reconstitution of 
macrophage expressing LpL in LpL knockout models led to increases in macrophage populations 
in the arterial wall. Macrophage-associated LpL may increase “anchoring” of LDL and 
macrophages. 
n-3 FA decrease the presence of inflammatory macrophages and LpL; hence are 
associated with less arterial cholesterol delivery, inflammation and atherosclerosis. In an 
atherosclerosis-prone mouse model (LDLR-/-), gradual replacements of SAT with n-3 
  
ameliorates abnormal lipid profiles and atherosclerosis. Thus, n-3 FA decrease risk for CVD in 
part by decreasing arterial macrophage-associated LpL.  
Interacting factors, such as PPARβ/δ, likely play an important role in regulation of 
arterial-wall LpL levels in response to FA. Increased arterial Foxo1 expression can contribute to 
decreased PPARα levels in the group fed n-3 FA. The levels of GPIHBP1 in the arterial wall 
correlate with arterial macrophage number. This indicates the existence of other pathways 
important in mediating changes in LpL levels and arterial lipid deposition. These studies as 
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CHAPTER 1 : INTRODUCTION 
A. SIGNIFICANCE OF DIETARY FATTY ACIDS AND CARDIOVASCULAR DISEASE 
Cardiovascular disease (CVD) has been the leading overall cause of death in the United 
States since 1900, and risk factor control remains a challenge for many (American Heart 
Association). Diet plays an important role in the development and prevention of CVD. Diets high 
in saturated fats increase the prevalence of atherosclerotic CVD morbidity and mortality 
(Mozaffarian and Ludwig, 2010). On the other hand, omega-3 fatty acids (n-3 FA), especially 
fish oil-derived eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have emerged as 
bioactive molecules that are potentially preventive and therapeutic agents to decrease CVD by 
acting on pathways related to atherosclerosis and myocardial infarction (Wang et al., 2006).  
Arterial low-density lipoprotein (LDL) cholesterol deposition is a key step in initiating 
atherogenesis. LDL retention in atherosclerosis-susceptible sites results from increased flux into 
the arterial wall, as well as from reduced lipoprotein efflux (Tabas, 1994). Mechanisms of LDL 
cellular uptake vary among different tissues (Calvo et al., 1998, Brown and Goldstein, 1986, 
Febbraio et al., 2000). In addition to whole LDL particle uptake, selective LDL-core lipid 
uptake, particularly cholesteryl esters (CE), has been reported in lipoprotein lipase (LpL)-rich 
tissues (Green and Pittman, 1991, Rinninger et al., 1995, Seo et al., 2005, Seo et al., 2000). 
Increased LpL in the arterial wall has been shown to increase LDL-CE deposition by enhancing 
LDL whole particle uptake and CE selective uptake (SU). This process can be promoted by 
feeding with high fat diets enriched in saturated FA in animal models (Seo et al., 2005). 
However, the mechanisms whereby certain FA increases arterial LpL levels are not fully defined.  
The overall goal of the studies described herein was to investigate pathways underlying 





development of atherosclerosis. Several mouse strains (C57BL/6, transgenic rescue-insulin 
receptor-deficient (L1) mice and LDL receptor-deficient mice) have been used as a wild type, 
insulin resistant or atherosclerosis-prone model, respectively, in in vivo studies. In addition, mice 
with LpL deficiency in the arterial wall were studied before and after LpL reconstitution in the 
artery. The data presented in this thesis demonstrate that specific conditions, such as the presence 
of high levels of saturated FA and insulin resistance, alter recruitment of different cell 
populations to the arterial wall, particularly accumulation of macrophages that secrete LpL, and 
thus favor the development of atherosclerosis. n-3 FA decrease the presence of inflammatory 
cells (and hence LpL) and are associated with protection from arterial cholesterol delivery, 
inflammation and atherosclerosis. The presence of arterial LpL itself also seems important for 
the presence of macrophages in the arterial wall. Interacting factors, such as PPARβ/δ, likely 
play an important role in regulation of arterial-wall LpL levels. These findings of “beneficial 
effects” of dietary n-3 FA on processes related to atherosclerosis can be important to future 













B. BACKGROUND  
The major goal of the thesis work was to define the underlying mechanisms of the control 
and regulation of dietary FA on LpL in the development of atherosclerosis.  Relevant 
background related to these studies is presented below. 
Fatty Acid Metabolism in Human Health and Disease 
Fatty acid metabolism  
Dietary FA supply energy for the maintenance of caloric balance and body weight. FA 
can be bound to albumin or esterified with glycerol as triglycerides (TG) for transport and 
storage in humans. FA are classified by their chain length, number of double bonds, position of 
the first double bond from the methyl end, and cis versus trans configuration across the double 
bond. These differences are important determinants in biological effects that influence metabolic 
and health outcomes. Three main types of FA are metabolized by mammalian cells: saturated FA 
(SAT), which do not contain any double bonds; monounsaturated FA, which have a single 
double bond; and polyunsaturated FA (PUFA), which contain multiple double bonds. 
Unsaturated PUFA are further divided into three groups according to the position of the first 
double bond at the third (n-3), sixth (n-6) or ninth (n-9) carbon from the methyl terminal. 
Humans lack enzymes that introduce double bonds between carbon 1 to 9. Therefore, n-3 α-
linolenic acid (LNA), n-6 linoleic acid (LA) and their elongation products are essential nutrients 
for humans. Figure 1-1 shows the conversions of LNA to DHA and LA to arachidonic acid (AA) 
through the action of specific elongases and desaturases. As shown in Figure 1-1, n-3 and n-6 FA 
can compete at several steps for the same enzymes for elongation or desaturation. n-3 or n-6 FA 
serve as bioactive molecules and can be further converted into powerful signaling molecules, 





and the more recently identified docosanoids which are docosatrienes, neuronprotectins (NPD), 





Figure 1-1: Biosynthesis of n-3 and n-6 series fatty acids from their precursors.  
The terminal methyl group is carbon 1. n-3 and n-6 series of FA are termed according to the position 
of the first double bond: after carbon 3 and carbon 6, respectively. LA, linoleic acid; LNA, linolenic 
acid; AA, arachidonic acid; EPA, eicosapentanoic acid; DPA, docosapentanoic acid; DHA, 
docosahexaenoic acid; COX, cyclooxygenase; LOX, lipoxygenase; PG, prostaglandin; LT, 





Regulatory effects of dietary FA on arterial lipid uptake and other factors important in 
atherosclerosis  
This thesis will present the effects of specific types of dietary FA on arterial lipid uptake 
and other pathways of atherogenesis. A major health issue related to dietary lipids is the quality 
of fat in the diet. The consumption of certain fats, such as SAT, is associated with an adverse 
lipid/lipoprotein profile and increased prevalence of CVD and atherosclerosis (Dietary 
Guidelines for Americans, 2010). Dietary n-3 FA have been shown to improve several 
intermediate determinants of CVD risk. n-3 FA can ameliorate hypertriglyceridemia, reduce 
blood pressure and reduce arrhythmias (Jung et al., 2008, Adkins and Kelley, 2010, Sudheendran 
et al., 2010, De Caterina, 2011). These biological effects can be mediated by n-3 through a 
number of mechanisms, such as the incorporation of n-3 FA into cell membrane phospholipids; 
this results in changes in membrane fluidity by altering the properties of lipid rafts and caveolae, 
leading to modulate membrane-associated proteins and receptors activity. It has been reported 
that the membrane incorporation of n-3 FA decreases the generation of intracellular reactive 
oxygen species with a subsequent diminished activation of redox-sensitive transcription factors, 
such as nuclear factor-κB (NF-κB) (Massaro et al., 2002). There is also evidence that n-3 FA 
signal through G-protein coupled receptors to modulate inflammation and insulin-sensitizing 
effects in monocytes and macrophages (Oh et al., 2010).  Another action of n-3 FA relating to 
cardiovascular health is its interference with cell-membrane ion channels that produces 
manyeffects, including reducing arrhythmias (Nair et al., 1997, von Schacky, 2004). However, 
the effects of n-3 FA on reducing recurrence rates in people with atrial fibrillation are 
inconsistent (Kowey et al., 2010), Other biological effects mediated by n-3 FA are probably 





produce anti-inflammatory catabolites, such as NPD1 and resolvin1 (De Caterina, 2011). 
Additionally, n-3 FA have been shown to increase the stability of atherosclerotic plaques in 
humans (Thies et al., 2003). Vulnerable plaques are characterized by a thinning fibrous cap and 
enlarging lipid core. Increased circumferential stress on the plaque leads to risk for plaque 
rupture (Loree et al., 1992). The mechanisms behind n-3 FA-mediated plaque stabilization likely 
include the inhibition of monocyte infiltration into plaques and the reduction of inflammation 
produced by differentiated macrophages. The incorporation of n-3 FA into plaques has been 
shown to increase the thickness of the fibrous cap (Loree et al., 1992, Sudheendran et al., 2010).     
In the artery, FA affects the development of atherosclerosis. Incorporation of dietary FA 
into chylomicron remnants influences lipid accumulation in arterial macrophages (Botham et al., 
2005). When compared with remnants rich in n-3 FA, chylomicron remnants rich in saturated FA 
are taken up more rapidly by cultured macrophages and result in greater arterial lipid 
accumulation (De Pascale et al., 2006). Saturated FA can also trigger the accumulation of 
macrophages in arterial wall which contributes to atherogenesis by local secretion of pro-
inflammatory mediators.(Li et al., 2002, Hayek et al., 2005). In vitro studies have shown that  
saturated palmitic acid promoted inflammation in cultured murine macrophages by increasing 
mRNA gene expression levels of pro-inflammatory cytokines, such as interleukin-6 (IL-6), but 
n-3 EPA decreased these (Jung UJ, Chang CL, Deckelbaum RJ, unpublished data). The specific 
mechanisms on how and which dietary FA influence macrophage inflammatory responses are 
still not well-understood. Recent studies have demonstrated that saturated FA activate 
macrophage inflammation mainly through the activation of toll-like receptor (TLR)/ nuclear 
factor-кB (NF-кB)-mediated signaling (Chait and Kim, 2010). SAT can act directly as TLR4 





Nguyen et al., 2007), or the recruitment of TLR4 into lipid rafts for downstream activation of 
inflammatory gene response (Lee et al., 2004). Indirectly, saturated FA amplify 
lipopolysaccharide (LPS)-induced TLR4/NF-кB-mediated inflammation through the metabolism 
of SAT to ceramide and activation of PKC-δ /mitogen-activated protein kinase (Schwartz et al., 
2010). On the other hand, n-3 FA, including both EPA and DHA block LPS-induced NF-кB 
activation in macrophages (Lee et al., 2004). Evidence suggests that DHA inhibits TLR4/NF-кB 
activation by inhibiting TLR2 dimerization with TLR6 or TLR1 (Lee et al., 2003b). Also, the 
incorporation of DHA into the membrane alters lipid composition in rafts, resulting in disruption 
of TLR4 recruitment into lipid rafts and reduces downstream signaling (Wong et al., 2009). 
Studies by Maloney et al. (Maloney et al., 2009) have further indicated that TLR4-dependent 
activation of NADPH oxidase (NOX) is necessary for the pro-inflammatory effects of saturated 
FA in vascular tissues that exacerbates vasculature injury (Lassegue and Griendling, 2010). Still, 
the specific interaction of various FA and NOX has yet to be established. In addition, the 
interaction of two differet types of FA has been reported; for examples, unsaturated oleic acid 
has been shown to offset saturated palmitic acid-induced lipotoxicity by channelling palmitic 
acid into intracellular TG in CHO cells (Listenberger et al., 2003). 
FA may also affect binding and uptake of lipids in the arterial wall by macrophages 
probably through the actions of arterial LpL. In addition to its catalytic activity on TG, LpL can 
also serve as a bridging or anchoring molecule for LDL and other lipoproteins to cell surface 
(Yagyu et al., 2003, Merkel et al., 2002). Seo et al. reported that a diet high in SAT quadrupled 
arterial cholesterol delivery via total LDL and selective LDL-cholesterol uptake in mice, and that 
this was associated with increases in arterial wall LpL levels (Seo et al., 2005, Seo et al., 2002). 





atherosclerosis (i.e., cholesterol delivery and LpL at the levels of arterial wall). The studies 
presented herein will emphasize the effects of specific FA in accelerating or inhibiting 
mechanisms relating to atherosclerosis, especially in relation to effects on LpL in the arterial 
wall.  
 
Lipoprotein Metabolism and Atherosclerosis 
Lipoprotein metabolism 
 Lipoproteins are emulsion complexes used by the body to transport cholesterol, TG and 
other lipids. Different lipoproteins have different functions in lipid metabolism. All lipoproteins 
are composed of hydrophobic interiors rich in CE and/or TG, and amphiphilic exteriors which 
contain phospholipids and cholesterol and apolipoproteins that provide structure, help target 
lipoproteins for tissue uptake, and regulate metabolic pathways. Ingested fats and cholesterol are 
first packaged into chylomicrons, relatively large particles enriched in TG, in the small intestine. 
After chylomicron hydrolysis, cholesterol and TG are subsequently packaged into very low-
density lipoproteins (VLDL) in the liver for delivery to other tissues. VLDL is composed of only 
about 5% to 10% protein, and about 50% to 65% TG. As VLDL are hydrolyzed in blood, they 
become denser and lose TG and all but one of their apolipoproteins-apolipoproteinB (apoB) and 
LDL are formed. LDL contains a high percentage of cholesterol and CE. Surface remnants of TG 
rich lipoproteins increase levels of high-density lipoprotein (HDL) which remove excess 
cholesterol from the tissues and return it to the liver for disposal as bile acids or cholesterol in 






Arterial LDL-cholesterol delivery 
Uptake of cholesterol (primarily from LDL) and its deposition in the arterial wall are 
major contributors in initiating atherogenesis. LDL-cholesterol retained in atherosclerosis-
susceptible sites results from increased LDL in the arterial wall, as well as from reduced 
lipoprotein efflux (Tabas, 1994). LDL receptors (LDLR) are a major pathway and are critical for 
cholesterol delivery to many cell types (Brown and Goldstein, 1986). LDL receptors on the 
surfaces of cells bind apolipoproteins of LDL, allowing the cells to take up cholesterol through 
receptor-mediated endocytosis. When apoB binds to a LDL receptor, LDL enters the cell in a 
coated vesicle. The vesicle fuses with an endosome. The lower pH of the endosome causes the 
LDL to detach from the LDL receptors, which are then recycled to the cell surface. The vesicle 
then merges with a lysosome. The apolipoprotein is degraded into amino acids, and the CE is 
converted to cholesterol. These components can then be used by the cell. A genetic disease, 
familial hypercholesterolemia, is caused by genetic defects associated with the LDL receptor. 
The cells of individuals homozygous for these defects are unable to take up LDL, so the 
concentration of serum cholesterol is about 3 to 5 times higher than normal. Individuals 
homozygous for familial hypercholesterolemia often die of heart attacks as early as age 5 years 
(Brown and Goldstein, 1986). 
However, significant amounts of LDL are delivered to certain tissues, such as the arterial 
wall, independent of LDLR. These “non-classical” pathways include CD36 and other scavenger 
receptors which may play important roles in pathological arterial lipid accumulation (Calvo et 
al., 1998, Febbraio et al., 2000, Moore et al., 2005). Previous studies have demonstrated that 
LDL-core lipids, particularly CE, can be delivered to cells without concomitant cellular uptake 





Rinninger et al., 1995, Seo et al., 2005). Arterial LDL-CE delivery via SU is substantially 
increased in mice, under certain conditions, such as elevated plasma cholesterol levels, age, 
and/or the presence of atherosclerosis, where 50% or more of total LDL-CE uptake was 
accounted for by SU (Seo et al., 2005, Seo et al., 2000).   
This thesis presents studies that examine the potential influence of dietary FA on arterial 
LDL uptake and on LDL cholesterol deposition in atherosclerosis. The accumulation of LDL and 
its cholesterol in the walls of large arteries attracts blood monocytes, and infiltrated monocytes 
are differentiated into macrophages that allow for more intracellular lipid accumulation and 
inflammation, leading to formation of plaque. As the plaque undergoes continued inflammation, 
matrix degradation, hypoxia, angiogenesis, and cell death, its fibrous cap thins and its lipid core 
becomes necrotic, leading to the risk for plaque rupture (Sudheendran et al., 2010).  
 
Lipoprotein Lipase (LpL) 
LpL expression and regulation 
 LpL is a member of the lipase superfamily. LpL enzymatic activity was first discovered 
in 1943 when Paul Hahn observed that intravenous injection of heparin abolished postprandial 
hyperlipidemia (Hahn, 1943). Subsequent studies established that LpL is a lipolytic enzyme 
activated by apoCII, and participates in the efficient delivery of FA to tissues (Scanu, 1966). LpL 
is involved in the metabolism of all classes of lipoproteins, including the clearance of 
chylomicron remnants, formation of intermediate-density lipoprotein (IDL) and LDL from 
VLDL, and regulation of plasma HDL concentrations (Cryer, 1981, Mead et al., 2002, Goldberg, 





LpL is synthesized in parenchymal cells as a monomer. It then moves to the luminal 
surface of EC where it is anchored by ionic interactions with heparan sulfate proteoglycans 
(HSPG) or glycosylphosphatidylinositol-anchored HDL-binding protein 1 (GPIHBP1) as a 
dimer. Dissociation of the LpL dimer into monomers leads to the loss of catalytic function. LpL 
is predominantly expressed and active in adipose tissue and cardiac and skeletal muscle. Lower 
expression levels are found in macrophages, brain, lung, spleen and pancreatic β-cells (Braun 
and Severson, 1992).  
LpL levels and activity are regulated at transcriptional and posttranscriptional levels in a 
tissue-specific manner. The tissue-specific regulation of LpL has been shown to have major 
metabolic consequences on macronutrient fuel portioning, energy homeostasis, insulin action, 
and lipoprotein metabolism. Feeding status is important. After fasting, LpL activity decreases in 
adipose tissue but increases in muscles, whereas feeding results in an increase in adipose LpL but 
a decrease in muscle LpL (Doolittle et al., 1990). Such changes in LpL expression are mediated 
through the action of hormones, including insulin, glucocorticoids, and adrenaline, that modulate 
LpL at the post-transcriptional level (Braun and Severson, 1992). Mechanisms involved in post-
transcriptional control of LpL likely include changes of LpL mRNA stability, translation, LpL 
protein degradation, processing, secretion, translocation, and competitive inhibition by products. 
Many metabolic diseases have also been shown to alter tissue-specific LpL levels and activity. 
For example, plasma LpL levels and activity are reduced, but macrophage-derived LpL 
expression and activity are increased in patients with diabetes (Sartippour and Renier, 2000). 
Moreover, signal transduction has also been reported to alter post-translational regulation of LpL 
in macrophages through the actions of PI-3 kinase (Tengku-Muhammad et al., 1998, Tengku-





Transcriptional control mechanisms have also been identified in the regulation of LpL 
gene expression. A number of regulatory sequences in the LpL gene have been identified, 
including a CT motif that interacts with Sp1 and Sp3 transcription factors and is important for 
basal promoter activity (Yang and Deeb, 1998). A peroxisome proliferator response element 
(PPRE), which binds to heterodimers of peroxisome proliferator-activated receptor (PPAR) , , 
or β/δ and 9-cis retinoic acid receptor (RAR), has been shown to induce LpL gene transcription 
in liver, adipose tissue, and macrophages in response to fibrates, certain FA, glucose, and 
specific anti-diabetic agents. PPARγ can also function in silencing LpL gene expression in the 
presence of specific modulators (i.e., FA or endogenous eicosanoids) (Robinson et al., 1999). It 
has been shown that the regulation of LpL gene expression in adipose tissue by sterol can be 
mediated in part through sterol regulatory element binding protein (SREBP). In liver and 
macrophages, cholesterol mediated selective expression of LpL is through the binding of a liver 
X receptor/retinoid X receptor (LXR/RXR) heterodimer to an element present between exon1 
and exon2 (Zhang et al., 2001). However, the induction of LpL mRNA expression by these 
agents is not always accompanied by corresponding increases in LpL activity. For example, 
when treated with PPARα or PPARγ agonists in cultured cells, LpL mRNA and intracellular 
protein were increased, but LpL secretion and activity were reduced  (Gbaguidi et al., 2002).  
A number of genetic engineering mouse models of LpL have provided further insights 
into the importance of tissue-specific control of LpL in maintaining energy homeostasis. For 
example, humans with LpL deficiency have severely elevated blood chylomicron levels and are 
at risk for pancreatitis (Brunsell and Deeb, 2001). In mice, genetic loss of LpL adversely affects 





1995, Merkel et al., 1998). Overexpression of LpL in skeletal muscle and liver increases cellular 
accumulation of FA-derived metabolites (e.g., intracellular TG) and induces insulin resistance 
(Kim et al., 2001). Loss of LpL in adipose tissue and its overexpression in skeletal muscle 
reduced adipose development when these mice were crossed onto the obese ob/ob background 
(Weinstock et al., 1997). However, in non-obese mice, adipose stores are normal. This suggests 
alternative pathways of lipid storage or uptake. In pancreatic β-cells, both overexpression and 
deletion of LpL impaired insulin secretion (Pappan et al., 2005). Although tissue-specific effects 
of LpL are still being examined, the role of LpL in maintaining energy balance in specific tissues 
is clearly important. 
Suggested interacting factors 
Several newly identified factors are shown to be important in influencing LpL levels or 
activity. Among them, angiopoietin-like proteins (Angptls) affect LpL activity. Angptl3 and 4 
inhibit LpL activity and are associated with hyperglycemia. Knockout of either Angptl3 or 
Angptl4 in mice leads to increased levels of heparin-releasable LpL activity and decreased 
plasma TG levels, whereas the overexpression of Angptl3 or Angptl4 decreases LpL and 
increases plasma TG (Fujimoto et al., 2006, Koster et al., 2005). Binding of LpL to GPIHBP1 – 
another newly identified interacting protein with LpL protects the lipase against inactivation by 
Angptl3 and Angptl4 (Lee et al., 2009). 
GPIHBP1 is a endothelial molecule that can play an important role in the LpL-mediated 
lipolysis of chylomicrons (Beigneux et al., 2009). GPIHBP1 was first identified as a GPI-linked 
protein that facilitates the binding of HDL to cultured cells. GPIHBP1 is highly expressed in the 
muscle and adipose tissues, the same tissues that express high levels of LpL. In these tissues, 





demonstrated that GPIHBP1 mediates the transendothelial transport of LpL (Davies et al., 2010). 
Patients with the mutation of GPIHBP1 have chylomicronemia and extremely low levels of LpL 
in plasma (Davies et al., 2010, Olivecrona et al., 2010). It has been postulated that the strongly 
negatively charged acidic domain found in GPIHBP1 binds to the positively charged domains of 
apolipoproteins in chylomicrons and heparin-binding domains in LpL (Ory, 2007). The recent 
study by Gin et al. has demonstrated that, indeed, the binding of apolipoproteins (e.g., apoAV) to 
GPIHBP1 depends on interactions with GPIHBP1's acidic domain. Ly6 mutations in GPIHBP1 
that abolish LpL binding do not interfere with apoAV binding. Interestingly, the binding of 
chylomicrons to GPIHBP1-transfected cells is mediated by LpL. When LpL is absent, 
chylomicrons do not bind to GPIHBP1-expressing cells (Gin et al., 2011). Exactly how 
GPIHBP1 interacts with LpL and chylomicrons and/or other lipoproteins is still not clear.  Our 
studies will show that GPIHBP1 is not only expressed in the arterial wall macrophages but that 
its expression is regulated in part by dietary FA. 
Most recently, Foxo, a subgroup of the Forkhead transcription factor family, has been 
reported to enhance LpL expression in vitro and in vivo (Kamei et al., 2003). Increasing 
evidence suggests that Foxo proteins are important in mediating cell proliferation, apoptosis, and 
lipid metabolism (Barthel et al., 2005). Foxo can serve as a transcriptional coactivator, interact 
with CBP, p300, SRC-1 and PGC-1  and be recruited to promoters with Foxo binding sites, 
contributing to both positive and negative effects of Foxo proteins on gene expression. Foxo 
proteins can also modulate promoters lacking a Foxo binding site by binding to other 
transcription factors, such as nuclear hormone receptors. In adipose tissues, Foxo1 has been 





decreasing DNA binding by the PPAR -RXR complex (Van Der Heide et al., 2004). The 
underlying pathways of how Foxo modulates LpL levels are not well defined, but our studies 
indicate that n-3 feeding increases levels of arterial Foxo1 mRNA.  
Taken together, these studies have shown the potentials of these LpL interacting factors 
mainly on LpL levels and activity; however, evidence is lacking on the interaction of these 
interacting factors with LpL in the arterial wall. The thesis work to be presented here will 
characterize the effects of some suggested interacting factors for LpL in the arterial wall. The 
correlation of these factors and LpL will be analyzed. Moreover, the potential regulation of these 
factors by dietary FA will be presented. 
LpL in atherosclerosis 
 The focus of this thesis is to investigate the role of LpL in mediating atherosclerosis and 
the mechanisms underlying regulation of arterial LpL levels by dietary FA. Systemic LpL has 
been shown to have anti-atherogenic actions via two mechanisms: (a) acceleration of the hepatic 
removal of remnant lipoproteins by increasing lipolysis with subsequent reduction in levels of 
plasma TG and cholesterol, and (b) by elevating plasma HDL levels (Yagyu et al., 1999, Koike 
et al., 2002). However, elevated LpL mediated lipolysis products (FFA) can alter EC barrier 
function and cause vascular inflammation (Wan et al., 08). Zilversmit postulated that LpL 
converts chylomicrons into atherogenic remnant lipoproteins (Corey and Zilversmit, 1977). In 
contrast to its conventional role in lipolysis, arterial expression of LpL is a marker of 
atherosclerosis. Focal expression of macrophage LpL has been shown to stimulate 
atherosclerosis in mouse bone marrow transplant models (Babaev et al., 2000); the depletion of 
LpL in macrophages is associated with less atherosclerosis (Babaev et al., 1999). Binding and 





vitro studies have demonstrated that LpL associates with lipoproteins and binds to cell surface 
proteoglycans (PG) (Eisenberg et al., 1992, Mulder et al., 1992, Rumsey et al., 1992) to promote 
the cellular uptake of lipoproteins by acting as a “bridging” molecule (Galeano et al., 1998, 
Williams et al., 1992, Auerbach et al., 1996). LpL-LDL complexes probably bind to cell surface 
PG to increase the internalization of LDL both by receptor-mediated and receptor-independent 
pathways (Obunike et al., 1996, Seo and St.Clair, 1997). In vitro and in vivo studies from our 
laboratory further showed that higher LpL levels increased accumulation of LDL-CE via non-
SR-B1- or non-LDLR-mediated pathways in different cells and tissues (Seo et al., 2005) (Figure 
1-2). This is in agreement with other studies, which have shown that LDL-CE SU occurs in LpL-
rich tissues such as muscle, heart, and adipose tissues (Seo et al., 2000, Green and Pittman, 1991, 
Yla-Herttuala et al., 1991). Increases in arterial LpL also link to the presence of macrophages 
and smooth muscle cells (SMC) in atherosclerotic lesions and enhances proliferation of vascular 
















Metabolic Syndrome, Type 2 Diabetes and Coronary Heart Disease 
Type 2 diabetes (T2D) is one of the most common non-communicable diseases and has 
become a major risk factor of CVD. Approximately 200 million people worldwide have diabetes 
and this will increase to an estimated 333 million by 2025 (Diabetes Atlas, 2003). Metabolic 
syndrome represents a series of markers that have been reported to be strongly associatied with 
atherosclerotic CVD and T2D in many prospective studies and randomized clinical trials (Lakka 
et al., 2002, Haddad, 2002). T2D occurs after insulin resistance and hyperglycemia. 
Hyperglycemia may contribute to increased atherosclerosis via several mechanisms. Glucose can 
increase intracellular oxidative stress and generation of reactive oxygen species in EC, resulting 
in activation of redox sensitive transcription factors, such as NF-қB that induces inflammatory 
gene expression (Haddad, 2002). Glucose interacts with proteins by non-enzymatic mechanisms 
leading to generation of glycated proteins and advanced glycation end products (AGE), blocking 
 
Figure 1-2: LpL actions in circulation and the arterial wall. 
In plasma (left panel), catalytic-active LpL is anti-atherogenic by increasing TG-rich 
lipoprotein removal and increasing HDL levels. In artery and other tissues (right panel), LpL 







AGE and their receptor can reduce vascular disease in different animal models (Jakus and 
Rietbrock, 2004). Glucosamine, converted from glucose by enzymatic actions, increases 
expression of transforming growth factor (TGF)-α and - , leading to increased PG production by 
enhanced proliferation of vascular SMC (Duan et al., 2005). Although insulin resistance 
decreases plasma LpL levels, data from streptozotocin (STZ)-injected diabetic rat shows 
significantly elevated LpL activity in certain tissues, such as diabetic heart (Qi et al., 2004, 
Sambandam et al., 1999). Diabetes can also induce macrophage-derived LpL expression 
(Sartippour and Renier, 2000). Thus, arterial LpL is postulated to be another important pathway 
to promote atherosclerosis in diabetic subjects. The thesis work presented here will show the 
effects of insulin resistance on arterial LpL levels and distribution that are linked to pathways in 
atherogenesis.  
Moreover, fish consumption in humans has been shown to improve serum lipid profiles 
and markers of insulin resistance and inflammation (Lankinen et al., 2006). Animal studies have 
shown that n-3 FA supplementation can prevent high SAT diet-induced insulin resistance 
(Storlien et al., 1987).  Thus, part of the research presented here will show the effects of n-3 FA 
versus SAT intake on markers of metabolic syndrome and arterial lipid deposition in an animal 
model of insulin resistance. 
 
Macrophages in Atherosclerosis 
Macrophage physiology 
 Macrophages are present in all tissues. They are differentiated from circulating 
peripheral-blood mononuclear cells, which migrate into tissues in the steady state or in response 





the bone marrow that is the precursor of different cell types, including neutrophils, eosinophils, 
basophils, macrophages, dendritic cells, and mast cells. 
Macrophages are the primary mediators of the innate immune response (Hume, 2006). A 
key function of macrophages is phagocytosis (Dale et al., 2008). Macrophages can respond to 
endogenous stimuli that are rapidly generated after injury or infection. These early stimuli are 
typically produced by innate immune cells and can exert marked, butusually transient, effects on 
the physiology of macrophages. Macrophages can also respond to signals that are produced by 
antigen-specific immune cells. These adaptive signals are more focused and prolonged than 
innate immune stimuli and generally give rise to longer-term alterations in macrophages. In 
addition, macrophages themselves can produce several factors that influence their own 
physiology. Under these conditions, there is an enhanced recruitment of blood monocytes that 
differentiate into macrophages (Gordon, 1995).  
Cytokines produced by immune cells can give rise to macrophages with distinct 
physiologies (Martinez et al., 2008). “Classically activated” macrophages (M1) arise in response 
to interferon-γ, which can be produced during an adaptive immune response by T helper 1 (Th1) 
cells or CD8+ T cells or during an innate immune response by natural killer cells, and tumor-
necrosis factor, which is produced by antigen-presenting cells (O'Shea and Murray, 2008). 
“Alternatively activated” macrophages (M2) arise in response to IL-4 (Loke et al., 2007) or IL-
13 (Edwards et al., 2006), which can be produced during an adaptive immune response by Th2 
cells or during an innate immune response by granulocytes. M2 macrophages express arginase-1, 
mannose receptor and IL-4 receptor-α and are generated in response to various stimuli (Mosser 





ligands, glucocorticoids, apoptotic cells, or IL-10 (Gerber and Mosser, 2001, Strassmann et al., 
1994, Hasko et al., 2007, Erwig and Henson, 2007, Martinez et al., 2008).  
Arterial macrophages and inflammation in atherogenesis 
 Several in vivo studies suggest that the phenotype of a macrophage population within the 
host tissue can change over time. Although the exact mechanism is not clear, a phenotypic 
switch in the macrophage population has been reported during development of atherosclerosis. 
Atherosclerosis lesions are formed after the deposition of lipids to areas of intimal thickening in 
atherosclerosis-prone blood vessels. Macrophages gradually accumulate in this area, which is 
enriched in LDL and extracellular PG, and adhere. As atherosclerotic lesions progress, 
macrophages exhibit an inflammatory phenotype and produce cytokines that are associated with 
classical activation (Hansson and Libby, 2006). 
Oxidized LDL, LPS from gram-negative bacteria, cytokines and free radicals are 
example of mediators that can initiate the cascade of inflammation of the vascular wall (Libby, 
2008). Activated endothelium increases expression of leukocyte adhesion molecules, including 
vascular cell adhesion molecule (VCAM)-1, intracellular cell adhesion molecule (ICAM)-1 and 
E-selectin. Monocytes bind to the adhesion molecules on EC and subsequently transmigrate into 
the subendothelial space where they transform into macrophages. Macrophages are directed 
toward chemoattractant cytokines, such as macrophage chemoattractant protein (MCP)-1 
secreted by the vascular cells in response to the oxidized LDL. The macrophages that scavenge 
oxidized LDL become lipid-laden and convert into foam cells and fatty streaks. Lesion 
complications occur when SMC in the intima divide and produce extracellular matrix molecules, 
such as collagen, and the SMC in the media migrate to the intima and contribute to the formation 





Dietary FA have the ability to modulate inflammation in atherogenesis through several 
mechanisms as described in the previous section. Part of the studies of this thesis will show the 
effects of dietary FA on markers of inflammation in the arterial wall. Also, the data will show the 
potential regulation of the number of macrophages and macrophage infiltration in specific aortic 
layers.  
The studies described herein investigated the underlying mechanisms of LpL modulation 
of arterial lipid deposition in the development of atherosclerosis.  We hypothesized that specific 
FA (SAT and n-3) as well as insulin resistance alter the recruitment of different cell populations 
to the arterial wall that modulate arterial LpL levels and distribution (Figure 1-3). To test these 
hypotheses, we have undertaken a series of dietary studies in different mouse models, including 
inbred wild type mice and models of insulin resistance or atherosclerosis, to determine the 
effects of specific FA on LDL-cholesterol delivery, and the control and cells of origin of arterial 
LpL. The results demonstrated that dietary saturated FA and insulin resistance alter arterial cell 
populations, particularly the accumulation of macrophages that secrete LpL, and thus favor the 
development of atherosclerosis. Interacting factors, such as PPARβ/δ, likely play an important 
role in regulation of arterial-wall LpL levels. In contrast, n-3 FA decrease the presence of 
inflammatory cells and hence LpL and is associated with protection from arterial cholesterol 
delivery, inflammation and atherosclerosis. These findings provide novel insights into the effects 























Figure 1-3: Thesis hypotheses. 
Specific FA, SAT vs. n-3, alter the recruitment of different cell populations to the arterial wall that 






CHAPTER 2 : N-3 FATTY ACIDS REDUCE ARTERIAL LDL-
CHOLESTEROL DELIVERY AND ARTERIAL LIPOPROTEIN LIPASE 
LEVELS AND LIPASE DISTRIBUTION* 
 
SUMMARY  
Objectives- We had previously reported that SAT-enriched diets increase arterial CE deposition, 
especially from LDL-SU, and this was associated with increased arterial LpL. We now 
questioned how diets rich in n-3 FA influence arterial cholesterol delivery and arterial LpL 
levels.  
Methods and Results- C57BL/6 mice were fed chow or eucaloric high fat diets enriched in SAT 
or fish oil (n-3) for 12 weeks and were then injected with double radiolabeled or fluorescent-
labeled human LDL to separately trace LDL-CE and LDL-apoB uptake. SAT and n-3 diets 
increased plasma cholesterol levels similarly; n-3 diets lowered plasma TG concentrations. SAT 
increased arterial LDL-SU with significantly higher CE infiltration into aortic media. By 
contrast, n-3 markedly reduced total LDL uptake and CE deposition and abolished SU with LDL 
localized only in aortic intima. Disparate patterns of CE deposition between diets were consistent 
with distribution of arterial LpL; SAT diets induced higher LpL levels throughout the aorta, and 
n-3 diets decreased LpL levels and limited LpL expression to the aortic intima.  
Conclusions- Diets rich in n-3 decrease arterial total LDL delivery and abrogate LDL-SU in 
parallel with changing expression and distribution of LpL in the arterial wall. 
* This chapter is a slightly modified version of a previously published paper: 
   Chang CL, Seo T, Matsuzaki M, Worgall TS, Deckelbaum RJ. n-3 fatty acids reduce arterial    
   LDL-cholesterol delivery and arterial lipoprotein lipase levels  and lipase distribution.     







Arterial cholesterol uptake and deposition are major contributors to atherogenesis. LDL 
retention in atherosclerosis-susceptible sites results from increased flux into the arterial wall, as 
well as from reduced lipoprotein efflux. Although LDL uptake via LDLR is a major pathway and 
is critical for cholesterol delivery to many cell types, significant amounts of LDL are delivered to 
certain tissues, such as the arterial wall, independent of LDLR. These “non-classical” pathways 
include scavenger receptors, which may play important roles in pathological arterial lipid 
accumulation (Febbraio et al., 2000). We and others have previously demonstrated that LDL-
core lipids, particularly CE, can be delivered to cells without concomitant cellular uptake and 
internalization of whole LDL particles by a process known as SU (Rinninger et al., 1995, Seo et 
al., 2005, Seo et al., 2000). SU from HDL via scavenger receptor type B I (SR-BI) has been well 
characterized and is involved in steroidogenesis and reverse cholesterol transport.  LDL-SU was 
observed in mice, and among the sites of SU of LDL lipid were tissues that express abundant 
LpL such as muscle, heart, and adipose tissue (Green and Pittman, 1991). We previously 
demonstrated in cultured cells that LDL-SU was mediated via non-SR-BI-mediated pathways 
and that SU was markedly increased by LpL (Seo et al., 2002). Consistent with these findings, 
muscle LDL-SU was significantly increased in mice over-expressing human LpL in muscle (Seo 
et al., 2000). Moreover, feeding high SAT diets markedly increased the contribution of SU to 
total arterial LDL-CE deposition (Seo et al., 2005); in apoE knockout mice, 50% or more of total 
LDL-CE uptake was accounted for by SU. Thus, we suggest that this mechanism contributes an 
additional pathway for CE delivery in LpL-expressing cells (e.g., macrophages) and may 





It is of interest that Corey and Zilversmit and others reported a direct correlation between 
arterial LpL and extent of aortic cholesterol deposition (Corey and Zilversmit, 1977, O'Brien et 
al., 1992). In humans, atherosclerotic lesions are rich in LpL (Yla-Herttuala et al., 1991). In 
contrast with the well-documented adverse effects of saturated fats on CVD and atherosclerosis, 
consumption of unsaturated fats, particularly those enriched in very long chain n-3 FA such as 
EPA and DHA, potentially reduce the risk for CVD (Wang et al., 2006). Although several 
mechanisms have been postulated for anti-atherogenic roles of n-3 FA, little is known about how 
n-3 FA might affect pathways in the early development and progression of atherosclerosis, i.e., 
cholesterol delivery at the level of the arterial wall. 
In these studies, we show that diets rich in n-3 FA markedly reduce arterial LDL whole 
particle uptake and LDL-CE SU relative to a SAT diet and that these effects are independent of 
plasma cholesterol levels. We have developed new methods and approaches, including 
quantitative immunofluorescence (IFC), to analyze the levels and localization of LpL in the 
arterial wall. The data showed that changes in arterial LDL delivery and deposition were related 
to changes in LpL expression and distribution in the arterial wall. Our studies suggest that n-3 
fats decrease arterial CE deposition by reducing whole LDL particle uptake and abolishing 















I] iodide was purchased from DuPont NEN (Boston, MA). [1 , 2 (n)-
3
H] 
cholesteryl oleoyl ether ([
3
H] CEt) was purchased from Amersham Biosciences (Arlington 
Height, IL). Tyramine cellobiose (TC) was kindly provided by Dr. Franz Rinninger (University 
of Hamburg, Germany). BODIPY-C12, Alexa Fluor 568, 647, and SYTOX Green were 
purchased from Molecular Probes (Invitrogen, Carlsbad, CA). Polyclonal rabbit anti-human LpL 
antibodies were provided by Dr. Ira Goldberg (Columbia University, New York, NY) or were 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). C57BL/6 mice were purchased 
from the Jackson Laboratory (Bar Harbor, ME) and were maintained in-house at the Columbia 
University Medical Center Animal Facility. All experimental procedures were in accordance 
with Columbia University‟s institutional guidelines for use of laboratory animals and were 
approved by Columbia University‟s Institutional Animal Care and Use Committee.  
 
 
Table 2-1: Fatty acid composition of chow, SAT and n-3 diets. 
Individual FA are expressed as percent of total dietary long-chain FA. Values were calculated from diet 








Four-week-old male C57BL/6 mice weighing 15-18 g were placed on a normal chow 
(4.5% fat, w/w, Purina LabDiet-5053, Framingham, MA), or a high fat diet (21% fat, w/w) 
enriched in either n-3 or SAT (Seo et al., 2005) for 12 weeks (n>10 for each group, but for some 
n-3 analyses data was available from only 7-8 mice because of an  accidental feeding error in  a 
group of n-3-fed mice). n-3 and SAT diets were isocaloric with 42% of total calories from fat. 
The fat content of the SAT diet consisted of 71% saturated fat from coconut oil, 19% 
monounsaturated fat from olive oil, and 9% polyunsaturated fats from safflower and corn oil (TD 
97108, Harlan Teklad, Madison, WI). In the n-3 diet, half of the total fat was from menhaden oil 
enriched in EPA and DHA (960165, MP Biomedicals, Irvine, CA) with saturated, mono- and 
polyunsaturated fat (8%, 8%, and 6%, respectively, w/w) to prevent essential FA deficiency. 
Both the n-3 and SAT diets contained 0.2% cholesterol, whereas the chow diet contained 0.02% 
cholesterol (w/w). Table 2-1 details the FA composition of each diet. During the feeding period, 
blood was collected weekly and was measured for free FA (FFA) (NEFA C kit, Wako, Neuss, 
Germany), TG, and total cholesterol (Chol)  (Roche Diagnostics,. Indianapolis, IN) according to 
the manufacturer‟s procedures as previously detailed (Qi et al., 2002).  
 
Lipoprotein profiles and fatty acyl composition 
At the end of the feeding periods, plasma from each mouse was pooled and analyzed for 
changes in lipoprotein profiles and plasma fatty acyl composition among different diet groups. 
Lipoprotein profiles were analyzed using fast performance liquid chromatography (FPLC) 
(Yagyu et al., 2003). Pooled plasma injected was 500 l for each run. FA analysis was 





detector (GLC). Extracts from 30 μl of pooled mouse plasma samples from each diet group were 
chromatographed as methyl esters on a 30 m fused silica column with an internal diameter of 
0.25 mm. The column was wall-coated with 0.2 μm SP-2380. Helium was used as carrier gas. 
The split ratio was 17:1. The injector and detector temperatures were 200 ˚C and 250 ˚C, 
respectively. The column temperature was held at 80 ˚C for 5 min, and in a step-wise fashion 
then reached a plateau of 220 ˚C. The gas chromatograph was calibrated using a standard 
mixture of FA (Sigma, St. Louis, MO). A correction factor was applied to compensate for the 
lower ionization detector response to unsaturated FA relative to corresponding weights of 
saturated FA. Individual fatty acid methyl esters were calculated using the area corresponding to 
the C 15:0 internal standard. Results were normalized for weight percentage of each FA 
(Oliveira et al., 1997, Lepage and Roy, 1984). 
 
LDL preparation and labeling 
LDL (d = 1.025–1.055 g/ ml) was isolated from normolipidemic humans by sequential 
ultracentrifugation (Seo et al., 2005). We separated LDL at the narrower density gradient range 
to minimize the confounding effects of LDL of different size and heterogeneity. In addition, this 
fraction contains no or minimal apolipoprotein E (apoE) which can be present in lighter LDL 
fractions (d=1.019–1.025 g/ ml). Also, use of a “constant” human LDL source limits variability 
in mouse LDL associated with diet feeding to the host animals. Isolated LDL was labeled with 
two nonhydrolyzable markers, [
3
H] CEt and [
125
I] TC, to trace LDL-CE core and whole LDL 
particle uptakes, respectively (Seo et al., 2000). The calculated cholesterol/protein weight ratios 
of LDL ranged from 1.6–1.8 (n=20). Typical specific activities were 10–15 and 52–230 dpm/ng 
LDL protein for [
3
H] CEt and [
125





For fluorescent microscopy studies, isolated LDL was labeled with BODIPY-C12 and 
Alexa 568 to independently trace LDL-CE and whole LDL particle uptakes, respectively. 
Detailed procedures and characterization of fluorescent LDL were previously described (Seo et 
al., 2005). Our previous studies showed that data obtained by assaying total and selective arterial 
LDL uptake via either radio-labeled or fluorescent-labeled LDL were comparable and very 
similar (Seo et al., 2005). As previous, our labeling procedures also did not modify LDL physical 
properties or induce LDL oxidation (Seo et al., 2000, Seo et al., 2005, Rinninger et al., 1995). 
 
LDL uptake in aorta 
At the end of the feeding period, mice were injected with double radiolabeled human 




H-CEt as respective markers for LDL apoB and 
LDL-CE uptakes). Twenty-four hours after injection, animals were sacrificed and radioactivity 




I was determined in the whole aorta. SU was determined 
from the differences in actual LDL-CE delivery based on [
3
H] CEt (actual CE uptake) and CE 
uptake from LDL whole particle uptake estimated from 
125
I-TC, and LDL composition, as 
described previously (Seo et al., 2005).  
LDL-CE delivery via SU was expressed as
 




I ratios (>1 indicates SU) 
or percentage of LDL-CE
 
delivery via SU relative to total LDL-CE uptake to eliminate the 
potential
 
confounders of labeled LDL dilution and/or competition. Total LDL-CE
 
delivery was 
determined directly from [
3
H] CEt uptake and was
 
compared with estimated LDL-CE delivery 
from whole LDL particle uptake calculated from [
125
I] TC-apoB uptake (Seo et al., 2005). The 
contribution of SU to total LDL-CE uptake was
 







total LDL-CE uptake and was then expressed as the percentage of LDL-CE
 
delivered via SU relative to the total LDL-CE delivery. 
Because radioactivity in the aorta was substantially lower than
 
in the blood compartment, 
specific control experiments
 






I uptake associated with blood contamination.
 
Isolated arteries were 
extensively washed with saline containing
 
heparin and EDTA to remove any surface-bound 
blood contaminants.
 




I traced LDL-CE and apoB internalized
 
by cells within the arterial wall and not LDL adhering 
to the
 
surface of the arterial wall of mice. In addition, aortas from 5 mice were
 
isolated at 48 h 
rather than at 24 h (as in most experiments) to determine whether accumulated radioactivity in
 
the arterial wall was released back into blood compartment.
 
Arterial radioactivity at 48 h was 
unchanged compared with
 
that at 24 h, which indicated that radioactivity in the
 
arterial wall did 
not efflux from the arteries after LDL was
 
internalized in arteries. Thus, use of nonhydrolyzable 
tracers
 
for both apoB and LDL-CE eliminated or reduced the potential
 
confounders associated 
with extracellular aggregation and/ or
 
different turnover rates for apoB and LDL-CE (e.g., after
 
degradation in the arterial wall), because these would have affected
 
LDL-CE/ apoB ratios for SU 
determination.  
Alternatively, at the end of the feeding periods described above, mice were
 
injected with 
200 µg double fluorescent-labeled LDL (BODIPY-C12
 
and Alexa-apoB). Eight hours after 
injection, mice were extensively
 
perfusion fixed with a 4% paraformaldehyde solution. Isolated
 
aortas were sectioned (9 µm) with a cryomicrotome after
 
being embedded in Tissue-Tek OCT 
(Sakura Finetek U.S.A.).
 
BODIPY-C12 and Alexa fluorescence were recorded with a laser
 
scanning confocal microscope (Zeiss LSM-510) equipped with an
 





and x40 magnification. The microscope
 
settings were 488 and 543 nm (excitation wavelength) 
and 475–575 and 560 nm (emission wavelength) for BODIPY-C12 and Alexa, respectively. All 
samples were captured with the same exposure times for consistency.
 
To determine BODIPY-
C12/Alexa ratios, we quantitated fluorescence
 
intensity in the intima-medial layers of the aortic 
arch using ImageJ version 1.31 (National Institute of Health;
 
http://rsb.info.nih.gov/ij/). These 
quantitative analyses were performed
 
on at least 5 different sections of both proximal and distal
 
aortas in each mouse (n=5 for each mouse group) and the mean
 
of ratios determined for each 
group. The patterns of Alexa/BODIPY dual channel colocalization were confirmed by a 
threshold-based overlap analysis – a binary test of whether the 2 signals occur in the same or in 
different regions using ImageJ 1.41 with the Colocalisation plug-ins (Lachmanovich et al., 
2003). In analyzing for autofluorescence using arteries from animals not injected with 
fluorescent-labeled LDL, we found no contributions of autofluorescence at the same wavelengths 
used for analyses of either BODIPY or Alexa (data not shown). 
 
LpL localization and quantification in the arterial wall  
Arterial LpL proteins were visualized using immunohistochemical and 
immunofluorescent staining. For both procedures, sections were fixed in 4% paraformaldehyde 
then permeabilized in 1% detergent, Triton X-100 (Sigma-Aldrich), in phosphate-buffered saline 
(PBS) for 5 min at room temperature, respectively. The sections were washed three times and 
treated with 5% normal goat serum (Sigma-Aldrich) to block non-specific background staining 
before antibody application.  
Sectioned aortas from mice that were injected with double fluorescent-labeled LDL were 





polyclonal anti-human LpL antibody (1:20) with biotinylated anti-rabbit secondary antibody, 
followed by ExtrAvidin Alkaline Phosphatase in situ for measuring substrate product  (Rabbit 
ExtrAvidin Alkaline Phosphatase kit, Sigma-Aldrich) as described previously (Feng et al., 2003). 
The microscope settings for LpL were the same as described previously (Seo et al., 2005). 
Captured images were measured for LpL staining intensity in the arterial wall using ImageJ 
similarly as described above for fluorescence intensity quantification. Results from at least 10 
different sections of the same proximal aorta per mouse were averaged in each group (n= 4).  
In separate analyses, arterial LpL content was assayed by immunofluorescent staining, 
the method that has been well-established in our laboratory. Before antibody application, aorta 
sections were processed as described above. Sections were incubated with a primary anti-LpL 
antibody (raised in rabbit, Santa Cruz) for 24 h at 4 °C, or for 2 h if incubated at room 
temperature. Sections were then rinsed and incubated for 1 h in goat-anti-rabbit IgG conjugated 
with Alexa Fluor 647 (1:200, Molecular Probes); followed by incubation with a cell nucleus 
marker-SYTOX Green (1µM, Molecular Probes) for 30 min. After several washes in PBS, 
stained sections were mounted and coverslipped. Fluorescence in the arterial wall was analyzed 
using a laser scanning confocal microscope (LSM-510 META) equipped with an image-captured 
device at x10 and x40 magnifications as described above. Labeled nuclei and LpL were 
visualized by excitation at a wavelength of 488 nm with a 520–550 nm band-pass emission filter 
and by excitation at a wavelength of 633 nm with a 638 nm low-pass emission filter, 
respectively. 
We have also developed the method to quantitate arterial immunofluorescent stained LpL 
on each optical section, regions of interests (ROI), either aortic intima (~125x500 pixels) or the 





staining (SYTOX Green), which highlights arterial structure. All LpL markers within each ROI 
were semi-automatically counted using ImageJ, an open source image manipulation tool that is 
widely used for biomedical image processing (Abramoff, 2004). Analysis and counting of 
detected spots was achieved by scanning the image or selection until the edge of an object was 
found. Each optical section was adjusted for proper threshold and background subtractions for 
separating the correct signal from background. Particle sizes from 90 to 255 Grey were counted 
using the Analyze Particles function. Each group consisted of four to fivemice. For each artery 
sample, 10–20 sections were prepared and analyzed. Possible clusters of LpL signals are also 
determined by the Analyze Particles function, because it provides options for segmentation when 
studying the circularity and size of particles.  
Statistical analyses 
Student‟s t-tests of group means were used to compare endpoints and analysis of variance 
(ANOVA) was used to evaluate potential interactions between the diets. Statistical significance 














Effects of diet on body weight and plasma lipid profiles 
Mice fed SAT diets showed higher and more rapid weight gain compared with mice fed a 
chow or n-3 diet; this effect was noted in the first 2–3 weeks of the feeding (p<0.05). After 12 
weeks of feeding, SAT-fed mice weighed 27.7 ± 1.3 g, whereas chow- and n-3-fed mice weighed 





Figure 2-1: Effects of diet on body weight. 
Body weight was measured weekly in mice fed chow (open triangles), SAT (filled squares) and n-3 
(filled circles) diets (n>10) for 12 weeks. Each point represents the mean of 10 mice ± SD. * and # 



















Plasma fatty acyl composition 
At the end of the feeding periods, fatty acyl composition in plasma was determined by 
GLC. As shown in Table 2-2, oleic acid (18:1) and linoleic acid (18:2) were the major plasma 
FA under the chow diet similar to their contribution to the chow diet. The SAT diet tended to 
increase levels of 16:0, 16:1, 18:0 and 18:1 FA compared with the chow diet. Because all all 
plasma lipid levels were much higher when on SAT, this represents substantial increases in 
absolute levels of these FA. The SAT diets also significantly reduced levels of n-3 FA (20:5 EPA 
and 22:6 DHA). In contrast, mice fed the n-3 diets had  significantly increased n-3 EPA and 
DHA, which accounted for ~40% of plasma FA; increases in EPA were most pronounced 






At the end of each feeding period, plasma from each mouse was pooled and 2 pooled groups for each diet were 
analyzed for plasma fatty acyl composition (n =7 or more for each diet) using gas liquid chromatography (GLC) 
with duplicate GLC runs as described in Methods. Results are expressed in the mean weight percent ± SE. ND 




significant differences between SAT and n-3, and 
SAT and chow, respectively (p<0.05). 
 
chow SAT n-3 
12:0 1.77 ± 1.01 1.62 ± 0.51 ND 
14:0 0.25 ± 0.51 2.13 ± 0.86 ND 
16:0 15.21 ± 2.47 16.94± 1.67 10.80± 0.05 
16:1 0.51 ± 0.96 2.03 ± 1.31 2.43 ± 0.20 
18:0 8.97 ± 0.56 10.40 ± 0.30 12.93 ± 0.96a 
18:1 n-9 12.11 ± 3.13 19.22 ± 2.98 6.09 ± 1.46a 
18:2 n-6 33.55 ± 1.26 29.36 ± 3.03 9.79 ± 2.12a 
18:3 n-3 2.79 ± 1.31 1.62 ± 1.57 1.37 ± 0.05 
20:4 n-6 8.51 ± 2.12 9.58 ± 0.61 11.56 ± 0.61a 
20:5 n-3 1.47 ± 1.01 NDb 24.75 ± 1.06a 
22:6 n-3 9.93 ± 2.27 4.31 ± 0.76 b 15.97 ± 0.05a 
unknown 4.92 ± 2.47 2.79 ± 1.72 4.31 ± 2.53 
  









Plasma lipoprotein profiles 
Plasma lipid profiles were determined at the end of the feeding periods (Table 2-3). The 
SAT diets led to two-fold greater plasma FFA and TG levels (p<0.01) in mice compared with 
chow diets, a finding consistent with our previous report (Seo et al., 2005). By contrast, mice fed 
the n-3 diet had ~ 40 % lower plasma FFA and ~70% lower TG levels than chow-fed mice. Both 
SAT and n-3 diets led to similar increases in plasma total cholesterol levels compared with 
chow-fed mice (p<0.01), presumably because of  higher cholesterol content in these two diets 
(0.2% w/w) compared with the chow diet (0.02% w/w). Changes in TG levels were likely related 
to increases or to loss of VLDL pools as determined by FPLC in mice fed SAT vs. n-3 diets 
(Figure 2-2). These results are in agreement with other studies demonstrating that n-3 diets lower 
plasma TG levels (Harris, 1997). We previously reported that plasma clearance of injected 
radiolabeled LDL was not different in SAT or chow fed mice (Seo et al., 2005). Using similar 
methodology in our current studies, we found that LDL fractional catabolic rates (FCR) were not 
significantly changed in n-3 feeding as compared with chow or SAT diets (0.12 ± 0.04, 0.12 ± 




Table 2-3: Plasma lipid profiles of mice fed chow, SAT or n-3 diets. 
Four-week-old mice were fed chow, SAT and n-3 diets for 12 weeks (n>8). Blood samples were 
collected and determined for triglyceride (TG), total cholesterol (Chol), and free fatty acids (FFA) 

























Dietary effects on arterial LDL uptake 
In contrast to the adverse CVD events mediated by SAT diets, n-3 FA can potentially 
reduce risk of CVD (Wang et al., 2006). We examined arterial LDL uptake and SU in mice that 
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Figure 2-2: Plasma lipoprotein profiles in mice fed a chow, SAT or n-3 diet. 
Total cholesterol (Chol) (A) and triglycerides (TG) (B) levels were determined for each fraction after 
separation by FPLC. Elution fractions 2–10, 12–22, and 25–35 represent elution zones for VLDL, 






uptake as traced by [
3
H] CEt compared with the chow diets (Figure 2-3A), where there was no 
apparent significant increase in uptake of 
125
I-apoB (or whole LDL particles; this can be 
accounted for by dilution of the injected labeled LDL with endogenous lipoproteins [Figure 2-2, 
Table 2-2]). Thus, as judged by differences in whole LDL particle CE estimated uptake as actual 
measured CE uptake, the markedly increased LDL-CE uptake relative to LDL-apoB was 
associated with a four- to five-fold increase in SU. In contrast, mice fed the n-3 diets had a 
marked reduction of whole particle LDL uptake and LDL-CE uptake in the arterial wall. There 
was no notable SU from LDL in mice fed the n-3 diet. 
When changes in SU induced by the different diets were plotted as the percent of total 
arterial LDL-CE delivery that is accounted for by SU in individual animals (Figure 2-3B), SU 
contributed ~ 5–6% of total arterial LDL-CE delivery in mice fed a chow diet. Mice fed a SAT 
diet on average had a 4-fold increase of CE-uptake attributed to SU accounting for up to ~20% 
of total LDL-CE delivery. However, in mice that were fed n-3 diets, contribution of SU to 
arterial CE mass was absent or almost absent; arterial LDL-CE delivery by SU only contributed 
a non-significant 2.3% of total LDL-CE uptake. 
In the parallel studies, mice were injected with fluorescent BODIPY/Alexa labeled LDL 
to trace LDL-CE and -apoB, respectively (Figure 2-4). We previously reported that use of 
fluorescent labeled LDL produced very similar data compared with measuring SU by isotopic 
studies (Seo et al., 2005). Fluorescent labeling also allowed localization of both whole LDL 
particle uptake and LDL-CE SU in specific layers of the arterial wall. Of note, there was no 
evidence of atherosclerotic lesions or fatty streaks in any of the arteries when examined by 





compared with chow diets (likely because of dilution from non-labeled endogenous apoB 
lipoproteins) (Figure 2-4A). 
Still, the SAT diet strongly increased labeled LDL-CE uptake, indicating LDL-CE 
delivery via SU. The SAT diet caused a higher arterial LDL infiltration compared with the chow 
diet, and this was also associated with much higher quantitative levels of LDL-CE deposition via 
SU (Figure 2-4B). By contrast, uptake of LDL-CE traced by BODIPY, and of LDL-apoB traced 
by red Alexa was markedly reduced in mice fed a n-3 diet (Figure 2-4A), in keeping with the 
observation that net LDL influx was diminished by n-3 feeding as observed with the isotopic 
studies. Again, there was no arterial SU in mice fed the n-3 diet (Figure 2-4B). Of interest, as 
shown in Figure 2-4A, whole LDL particle (Alexa-apoB) and LDL-CE (BODIPY) in the arteries 
of chow and SAT fed groups were mostly in the intima-media regions of the aorta. However, in 
mice fed an n-3 diet, overall arterial LDL infiltration was much less; furthermore, nearly all 
LDL-CE and apoB co-localized strictly within the intimal and/or sub-endothelial area with much 
less deposition in the media. 
Patterns of fluorescence colocalization were confirmed by Colocalisation Plus-ins of 
ImageJ version 1.41 (Lachmanovich et al., 2003). Fluorophore patterns did not change after 
extensive washing with heparin containing perfusate indicating that the fluorophores were 
located inside the arterial wall and were associated with cells present in the arterial wall. Similar 
to our previous report (Seo et al., 2005), we found almost no SU, and little or no effects of diet 













































































































Figure 2-3: Arterial LDL and selective LDL-CE uptakes. 
Arterial LDL-CE calculated from apoB uptake and CE uptake measured directly (A). *, p<0.05, 
chow vs. n-3; **. p<0.05, chow vs. SAT. (B) Percent contribution of SU to total CE delivery in 



















































































































Figure 2-4: Effects of diets on fluorescent LDL uptake in aortas. 
Fluorescent LDL-apoB (Alexa) and LDL-CE (BODIPY) uptakes in aorta (A). (B) Ratios of arterial 
uptake of total LDL-CE to that of CE measured from whole LDL particle uptake (mean ± SE).  A 







Dietary fat changes arterial LpL levels and distribution 
Our previous studies showed that increased LpL in the arterial wall was linked to 
increased arterial LDL uptake and SU (Seo et al., 2005). We and others have demonstrated that 
LpL associates with lipoproteins and binds to cell surface PG, especially HSPG, to increase 
cellular uptake of LDL and other lipoproteins (Seo et al., 2000, Rumsey et al., 1992). In our 
current studies, using densitometry of Western analyses, we found that the different diets 
resulted in absolute differences in arterial LpL protein expression. The SAT diets increased 
arterial LpL levels 2.6-fold compared with chow diets as previously reported (Seo et al., 2005). 
By contrast, the n-3 diet reduced arterial LpL compared with the chow diet by 33% as averaged 
in two sets of experiments. 
Because our data (Figure 2-4) indicate that SAT and n-3 diets strongly affect distribution 
of LDL and CE deposition within the arterial wall, we examined whether these differences 
correlated with changes in arterial LpL distribution (Figure 2-5). Arterial LpL content and 
distribution were analyzed both by immunohistochemistry and IFC. Consistent with Western blot 
analyses, densitometric analyses of both assays showed that SAT diets significantly increased 
whereas n-3 diets decreased intensity of arterial LpL staining when compared with chow (Figure 
2-5A). By using the new techniques (quantitative IFC, developed in our laboratory), we were 
able to detect arterial LpL localization with a higher resolution and to quantify LpL IFC in 
different aortic layer. The results showed LpL was located consistently throughout the whole 
arterial section in chow-fed mice and even more intensely in SAT-fed mice. The n-3 diet led to a 
marked decrease in total LpL levels and markedly decreased aortic media LpL levels with 





To further elucidate the effects of dietary FA on arterial LpL distribution, arterial LpL 
was detected by rabbit polyclonal antibody with a secondary antibody conjugated with Alexa 
Fluor 647 (Figure 2-5B). Quantification of fluorophore-tagged LpL showed that, in contrast to a 
more than 2-fold increase of aortic medial LpL in SAT diets (p<0.05), n-3 diets markedly 
decreased aortic medial LpL levels by 80% as compared with SAT diets (p<0.01) (Figure 2-5C). 
Although aorta sections from n-3 fed mice had less LpL content on each optical section when 
compared with  chow-fed mice, intimal LpL was slightly increased in n-3-fed mice (p<0.05, 
Figure 2-5C), indicating arterial LpL can be disproportionally changed within different aortic 
layers (intima versus media) after SAT vs. n-3 feedings. Thus, distribution patterns of LpL in the 
arterial wall of mice fed different diets were very similar to those of LDL-CE uptake traced by 
BODIPY, suggesting a role for LpL and its distribution in the quantity and the location of LDL 










































































































































Figure 2-5: Effects of diet on arterial LpL content and distribution. 
 (A) Reddish-brown immumohistochemical staining shows LpL. (B) Confocal fluorescence of LpL. 
LpL is seen as the green dots. (C) Quantification of LpL in aortic media and intima (mean ± SE). *, 







Atherosclerosis correlates with increased lipid deposition and lipoprotein retention in the 
arterial wall (Williams and Tabas, 1995). In humans, excess cholesterol delivery occurs 
primarily through LDL, the predominant cholesterol carrying lipoprotein. Higher LDL blood 
concentrations with concomitant increased arterial wall cholesterol deposition are associated 
with increased risk for CVD. Moreover, extent and severity of atherosclerosis, a major 
contributor to CVD, is modulated by type of dietary fats. Diets enriched in saturated fat promote 
CVD, whereas diets rich in n-3 fats can lower CVD morbidity and mortality (Deckelbaum and 
Akabas, 2006, Mozaffarian and Rimm, 2006). Although some recent studies did not show 
positive effects of n-3 FA on reducing mortality rates for CVD, we speculate that the effects of 
n-3 FA were possibily affected by several confounders, such as low doses of n-3 
supplementation, small sample sizes, shorter periods of trial time and aggressive medical 
treatments (Rauch et al., 2010, Kromhout et al., 2010). In our studies, we investigated the early 
events that link to atherogenesis; we examined how different dietary fats directly influence 
delivery of LDL-CE to the arterial wall, differentiating between whole particle LDL and 
selective LDL-CE uptake before development of atherosclerotic lesions. We demonstrate that a 
SAT-rich diet increases arterial LDL-CE uptake and markedly increases SU compared with a 
chow diet, and that a n-3-rich diet significantly reduces both arterial apoB and LDL-CE uptake, 
with relatively little or no SU. Our studies show that mice fed the n-3 diet had a substantial 
reduction in plasma FFA and TG levels that were associated with a decrease in plasma TG-rich 
particle lipoprotein pools. Plasma cholesterol levels, however, were increased by both SAT and 
n-3 diets to a similar degree compared with a chow diet, suggesting that the observed changes in 





We previously demonstrated that plasma cholesterol levels and advancing atherosclerosis 
could explain, in part, changes in LDL uptake and SU in mice fed a SAT diet. In fact, using 
apoE-null mice as a model, we found that with developing arterial atherosclerosis, SU could 
contribute to almost 60% of total LDL cholesterol delivery to the arterial wall at high plasma 
cholesterol levels. These observations are consistent with other studies of atherosclerosis in 
humans and in animal models (Rinninger et al., 1995, Seo et al., 2005). Interestingly, our current 
studies evaluating the effects of n-3 FA did not follow this paradigm; even with increased levels 
of plasma cholesterol, the n-3 diet decreased LDL uptakes. Our results are consistent with studies 
by Weiner et al., who demonstrated that n-3 FA reduced development of coronary 
atherosclerosis in pigs after a catheter injury, regardless of plasma lipid profiles (Weiner et al., 
1986). Because  in the current study the effects of decreased total LDL uptake and SU in mice on 
n-3 diets compared with SAT diets cannot be attributed to differences in plasma cholesterol 
levels, other factors must underlie the effects of n-3 FA. Our studies suggest that atherogenic 
effects of LDL could relate to the level and localization of arterial LpL. In our studies, we used 
both radioisotopes and fluorescent tags to trace LDL-CE and whole particle uptake in mouse 
artery and documented similar results obtained by both methods. Our novel approach of using 
double fluorescent-labeled LDL enabled us to localize LDL-CE and LDL whole particle 
distribution in the arterial wall before development of atherosclerosis. 
Arterial LpL content has been recognized to correlate with accumulation of arterial wall 
CE in rabbit models for atherosclerosis (Corey and Zilversmit, 1977). Increases in arterial LpL 
link to the presence of macrophages and SMC in atherosclerotic lesions. LpL enhances 
proliferation of vascular SMC in vitro (Mamputu et al., 2000). Babaev et al. (Babaev et al., 2000) 





LpL stimulates atherosclerosis in mice. In vitro studies have demonstrated that LpL associates 
with lipoproteins and binds to cell surface PG, especially HSPG (Eisenberg et al., 1992), to 
promote the cellular uptake of lipoproteins by acting as a “bridging” molecule (Williams et al., 
1992). LpL-LDL complexes can bind to HSPG to increase the internalization of LDL both by 
receptor-mediated and receptor-independent pathways (Obunike et al., 1996). Our own in vitro 
and in vivo studies further showed that elevation of LpL levels increased accumulation of LDL-
CE via non-SR-B1- or LDLR-mediated pathways in different cells (Seo et al., 2005, Seo et al., 
2000). This is in agreement with other studies that have shown that LDL-CE SU occurs in LpL-
rich tissues such as muscle, heart, and adipose tissues (Green and Pittman, 1991). 
What are possible mechanisms for the differential effects of dietary FA on cholesterol 
deposition in the arterial wall? A high-fat or Western diet has been shown to increase LpL levels 
in rabbit adipocytes and muscle (Sartippour and Renier, 2000). LpL itself enhances cellular PG 
production (Obunike et al., 2000, Mamputu et al., 2000). Camejo et al. (Camejo et al., 2002) 
reported that higher concentrations of saturated FA induced SMC extracellular matrix alterations 
with more trapping of LDL with longer retention time; a condition which would favor SU (Seo et 
al., 2000). Therefore, we propose that increasing arterial PG and LpL levels will lead to 
synergistic effects in increasing early aortic cholesterol deposition via anchoring and retention of 
LDL, similar to interactions recently reported in atherosclerotic lesions in apoB transgenic mice 
(Gustafsson et al., 2007). High levels or intake of saturated FA, respectively, in vitro or in vivo, 
can thus lead to a “vicious cycle” of increased LpL levels and increased numbers of arterial wall 
macrophages and SMC. This combined with increased PG, could result in increased cholesterol 
deposition in the artery. In contrast to saturated FA, n-3 FA have quite different effects on 





macrophages and induce macrophage and SMC apoptosis, thus inhibiting atherogenesis (Chinetti 
et al., 1998). n-3 FA, such as EPA, can inhibit LpL activity by 50–60%. Adding EPA to media of 
cultured J774 macrophages markedly decreased LpL transcription and translation, whereas 
adding SAT had the opposite effects  (Michaud and Renier, 2001). A n-3-rich diet probably also 
inhibits structural changes in vascular SMC and inhibits macrophage accumulation to decrease 
SU. 
In the current studies, similar to others, we suggest that LDL-cholesterol accumulation is 
one key pathogenic event and requirement for lesion development in early atherosclerosis 
progression. However, there are many other factors that can affect binding uptake and the flux of 
lipoproteins to the artery. One such factor is shear stress. Although, we have not accounted for 
changes in shear stress in terms of LDL uptake, the hemodynamic stress is a prerequisite, 
because atherosclerosis does not develop within the venous system due to a low pressure-lower 
shear stress environment. Also pulmonary arteries do not develop atherosclerosis unless 
pulmonary hypertension is present. Another possibility that might influence LDL accumulation 
in the arterial wall is the changes in vascular permeability. A significant body of evidence 
supports the involvement of LpL in lipoprotein interactions within the arterial wall. It has been 
demonstrated that LpL associated lipolysis increased arterial permeability to lipoproteins 
(Rutledge et al., 1997), although lipolysis was not studied in our studies herein. 
It is of interest that the distribution patterns of LpL and LDL-CE from immunohistology 
and immunofluorostaining are highly comparable; there is deeper infiltration of LDL with 
increased medial LpL in SAT fed mice. By contrast, LpL and LDL remain in the intimal layer 
with less lipid penetration in n-3-fed mice. At this point, it is unknown what mechanisms are 





however, the n-3 diet may be beneficial in preventing deeper LDL infiltration into the arterial 
wall. We reported that addition of LpL to perfusates of TG-rich particles markedly diminished 
their penetration into arterial wall media (Mullick et al., 2002). These conditions were different 
from our current studies, where LpL intimal concentration would result from redistribution of 
endogenous arterial LpL or would be derived from exogenous LpL from other tissues. As 
suggested above, LpL at the intimal level might indeed prevent deeper LDL infiltration into the 
arterial wall. Taken together, LpL facilitates the binding of lipoproteins to extracellular PG by 
acting as a bridging molecule, and modulates arterial LDL-cholesterol accumulation. n-3 FA can 
reduce total arterial LpL levels and, we hypothesize, at the intima decrease vascular permeability 
to LDL and its penetration into arterial wall. 
It is possible that increased LDL in arteries from mice fed SAT diets might be derived 
from the vasa vasorum. In our current studies, we have not observed any vascular remodeling 
and neovascularization of the intima or media. Although it is unlikely that increased cholesterol 
delivery in SAT-fed mice can be directly linked to vasa vasorum, we cannot exclude this 
possibility. 
Our current studies were carried out in mice with no identifiable atherosclerotic lesions 
(e.g., fatty streaks). In our previous reports, we showed that events associated with 
atherosclerosis progression, such as increasing plasma cholesterol levels and lesions themselves, 
modulate SU (Arai et al., 1999, Seo et al., 2005). Now we demonstrate that SU can be an 
important contributor to accelerated arterial CE uptake even before to the appearance of 
atherosclerotic lesions. Moreover, cholesterol delivery to the arterial wall is modified by diet, in 
part, through regulating arterial LpL levels even before atherosclerosis develops. LpL is known 





Thus, in Chapter 3, we asked whether n-3 FA influence arterial LDL uptake and deposition and 























CHAPTER 3 : N-3 FATTY ACIDS DECREASE ARTERIAL LDL-
CHOLESTEROL DELIVERY AND LIPOPROTEIN LIPASE LEVELS IN 
INSULIN RESISTANT MICE ** 
 
SUMMARY  
Objectives- Insulin resistance contributes to risk for CVD. In Chapter 2, we described how 
arterial LDL-cholesterol deposition from LDL total and SU was increased by SAT and decreased 
by n-3 FA; this was associated with increased or decreased arterial LpL, respectively. We now 
questioned whether n-3 FA would also influence arterial cholesterol delivery and LpL levels in 
insulin resistant mice.  
Methods and Results- Insulin receptor transgenic knockout mice (L1) were fed a chow, SAT or 
n-3 diet for 12 weeks. Double fluorescent BODIPY-CE and Alexa labeled human LDL was 
injected to separately trace LDL-CE and LDL-apoB whole particle uptake. In contrast to SAT 
diets, n-3 diets markedly reduced all plasma lipids, ameliorating progression of insulin 
resistance. As opposed to SAT, n-3 reduced arterial LDL uptake, CE deposition and SU. 
Disparate patterns of CE deposition between diets were comparable with arterial LpL 
distribution; SAT induced high LpL levels throughout aortic media; LpL was limited only to 
intima in n-3 fed mice.  
Conclusion- n-3 FA diminish arterial LDL-cholesterol deposition in mice with insulin resistance 
and this is associated with changes in arterial LpL levels and distribution. 
 
** This chapter is a slightly modified version of a previously published paper:  
Chang CL, Seo T, Du CB, Accili D, Deckelbaum RJ. n-3 fatty acids decrease arterial low-
density lipoprotein cholesterol delivery and lipoprotein lipase levels in insulin-resistant mice. 






CVD remains the leading overall cause of death in the United States. Type 2 diabetes, 
one of the most common non-communicable diseases, has emerged as a major CVD risk factor; 
patients with type 2 diabetes have a two-  to four- fold greater risk than individuals without 
diabetes for developing atherosclerosis, and that increases prevalence of CVD morbidity and 
mortality (Haffner et al., 1998). Insulin resistance is an important pathophysiological defect 
underlying the current epidemic of CVD and type 2 diabetes. Insulin resistance usually starts 
with impaired insulin action or sensitivity in the regulation of blood glucose and commonly leads 
to hyperinsulinemia, elevated plasma FFA levels, and later to type 2 diabetes (Nigro et al., 2006).  
LpL has been postulated to be another important contributor to atherosclerosis promotion 
in patients with diabetes. Although low circulating LpL activity is observed in insulin resistance 
and type 2 diabetes mellitus and is linked to premature atherosclerosis (de Vries et al., 2003), 
macrophage-derived LpL levels and activity are increased in animals and humans with insulin 
resistance and diabetes (Sartippour and Renier, 2000). Thus, it is likely that these differential 
effects on LpL levels in specific tissues and cells might lead to many pro-atherogenic events by 
promoting focal lipid deposition (Seo et al., 2005) (e.g., in the arterial wall) while reducing 
lipoprotein clearance in the circulation.  
Dietary FA have been reported to have direct regulatory effects on LpL expression and 
activity. Our recent studies showed that an n-3 FA-rich diet markedly reduced arterial LDL 
whole particle uptake and LDL-CE SU relative to a SAT-rich diet in mice, independent of 
plasma cholesterol levels (Seo et al., 2005, Chang et al., 2009). We and others have previously 
demonstrated that LDL-core lipids, particularly CE, can be delivered to cells without 





Rinninger et al., 1995). Unlike HDL SU, LDL SU was not mediated by SR-B1 but can be 
markedly increased by LpL (Seo et al., 2002). Moreover, feeding with high SAT diets markedly 
increased the contribution of SU to total arterial LDL-CE deposition (Seo et al., 2005); in apoE 
knockout mice, 50% or more of total LDL-CE uptake was accounted for by SU. Thus, we 
suggest that this mechanism contributes to an additional pathway for CE delivery in LpL-
expressing cells (e.g., macrophages) and may contribute to pathological accumulation of CE.  At 
the level of the arterial wall, we postulate that increased LpL levels by a SAT diet increase LpL 
“bridging” activity, which is associated with trapping more LDL and selective LDL-CE uptake 
(Chang et al., 2009, Seo et al., 2005). By contrast, n-3 fats decrease arterial LpL and arterial CE 
deposition with markedly reduced whole LDL particle uptake and essentially no arterial SU from 
LDL. 
We now questioned how n-3 FA influence arterial LDL-cholesterol delivery and LpL 
levels in an insulin-resistant model; mice that lack insulin receptors in every tissue except liver, 
pancreatic β-cells, and some parts of the brain (Okamoto et al., 2004). Thus, these mice [referred 
to as L1 (Okamoto et al., 2004)] are a model of insulin resistance in all cell types of the arterial 
wall. The L1 mouse model overcomes issues that are usually associated with other models of 
insulin resistance, such as issues of obesity-related leptin signaling defect or the abnormalities in 
lipid metabolism induced by hepatic insulin resistance. This allows us to directly analyze the 
effects of impaired insulin signaling in vascular tissues. We selected this model to demonstrate 
the effects of dietary FA, SAT versus n -3, on lipid uptake in the arterial wall.  Our results show 
that L1 mice were very prone to the accumulation of arterial LDL-CE via SU and this was linked 
to the elevated arterial LpL levels. SAT diets induced more severe insulin resistance and 





mice. By contrast, n-3 fats ameliorated abnormal plasma lipid profiles in L1 mice and reduced 
arterial LpL levels and total LDL and selective CE uptakes. In the current studies, in addition to 
quantifying immunofluorescence of LpL, we developed the new techniques to analyze the 
correlation of arterial LpL and macrophages. Colocalization of LpL and aortic macrophages 























Materials and Animals 
BODIPY-C12, Alexa Fluor 488, 546, 568 and 647 were purchased from Molecular 
Probes (Invitrogen, Carlsbad, CA). Rat anti-CD31 antibody was purchased from BD Pharmingen 
(San Jose, CA). Polyclonal rabbit anti-CD68 antibody was purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA). LpL antibodies were provided by Dr. Ira Goldberg (Columbia 
University, New York, NY) for immunohistochemistry and Western Blots and by Dr. Gunilla 
Olivecrona for IFC (Umea University, Umea, Sweden).  L1 mice have been described in a 
previous publication (Okamoto et al., 2004). These mice were
 
generated by intercrossing mice 
bearing a transthyretin-driven
 
human INSR cDNA with Insr heterozygous knockout mice, L1 
mice lack endogenous Insr and express the human
 





The genetic makeup of these mice contains chromosomes
 
derived from 
129SV, C57BL/6, and FVB genomes, and animals were maintained on a mixed background. All 
animals were kept in-house at the Columbia University Medical Center Animal Facility. All 
experimental procedures were in accordance with Columbia University‟s institutional guidelines 
for use of laboratory animals and were approved by Columbia University‟s Institutional Animal 
Care and Use Committee. 
 
Feeding Protocols 
Four-week-old male L1 mice weighing 15-18 g were placed on a normal chow (45g total 
fat/kg diet, Purina LabDiet-5053, Framingham, MA), or a high fat diet enriched in either n-3 or 
saturated fats for 12 weeks (n > 10 for each group) (Seo et al., 2005). The high fat diets were 





for n-3 or SAT diets, respectively. The fat content of the SAT diet consisted of 71% saturated fat 
from coconut oil, 19% monounsaturated fat from olive oil, and 9% polyunsaturated fats from 
safflower and corn oil (TD 97108, Harlan Teklad, Madison, WI). In the n-3 diet, half of the total 
fat was from menhaden oil enriched in EPA and DHA (960165, MP Biomedicals, Irvine, CA) 
with saturated, monounsaturated and polyunsaturated fats (8%, 8%, and 6%, respectively, w/w) 
to prevent essential FA deficiency. Both the n-3 and SAT diets contained 2 g cholesterol, 
whereas the chow diet contained 0.2 g cholesterol per kg of diet. FA composition of each diet 
was detailed previously (Chang et al., 2009). During the feeding period, blood was collected 
weekly and assayed for FFA (NEFA C kit, Wako, Neuss, Germany), TG and total cholesterol (T-
Chol) (Roche Diagnostics, Indianapolis, IN) according to the manufacturer‟s procedures as 
previously detailed (Seo et al., 2002). Blood glucose and insulin levels were determined after 
mice were sacrificed at the end of a feeding period with 2 h fasting as previously described 
(Okamoto et al., 2004). 
 
Lipoprotein profiles 
At the end of the feeding period, plasma from each mouse was pooled and analyzed for 
changes in lipoprotein profiles among different diet groups using FPLC (Yagyu et al., 2003). 
Pooled plasma injected was 500 l for each run.  
 
LDL preparation and labeling 
LDL (d = 1.025–1.055 g/ml) was isolated from normolipidemic humans by sequential 
ultracentrifugation (Seo et al., 2005). We separated LDL at the narrower density gradient range 





fraction contains no or minimal apoE which can be present in lighter LDL fractions (d=1.019–
1.025 g/ml). Also, use of a “constant” human LDL source limits variability in mouse LDL 
associated with diet feeding to the host animals.  
Isolated LDL was labeled with fluorescent BODIPY-C12 and Alexa 568 to 
independently trace LDL-CE and whole LDL particle uptake, respectively. Detailed procedures 
for labeling and characterization of fluorescent LDL were described previously (Seo et al., 2005, 
Chang et al., 2009). Our previous studies showed that data obtained by assaying total and 
selective arterial LDL uptake via either radiolabeled or fluorescent-labeled LDL were 
comparable and very similar (Seo et al., 2005). As previously described, our labeling procedures 
also did not modify LDL physical properties or induce LDL oxidation (Seo et al., 2000, Chang et 
al., 2009, Seo et al., 2005, Rinninger et al., 1995). 
 
LDL uptake in aorta 
At the end of the feeding period described above, L1 mice were
 
injected with 200 µg 
double fluorescent-labeled LDL (BODIPY-CE
 
and Alexa-apoB). Eight hours after injection, 
mice were sacrificed and extensively
 
perfusion fixed with a 4% paraformaldehyde solution. 
Isolated
 
aortas were sectioned (12 µm) with a cryomicrotome after
 
being embedded in Tissue-
Tek OCT (Sakura Finetek).
 
BODIPY-C12 and Alexa 568 fluorescence were recorded with a 
laser
 
scanning confocal microscope (Zeiss LSM-510) equipped with an
 
image-capture device at 
x20 and x40 magnification. The microscope
 
settings were 488 and 543 nm (excitation 
wavelength) and 475–575 and 560 nm (emission wavelength) for BODIPY-C12 and Alexa, 
respectively.
 
All images were captured with the same laser intensity, gain, and exposure times.
 
To determine BODIPY-C12/Alexa ratios, we quantitated fluorescence
 





medial layers of the aortic arch using ImageJ version 1.31 (National Institute of Health;
 
http://rsb.info.nih.gov/ij/). These quantitative analyses were performed
 
on at least five different 
sections of proximal aortas in each mouse (n=5 for each mouse group), and the mean
 
of ratios 
normalized for unit area of artery sections was determined for each group. The patterns of 
Alexa/BODIPY dual-channel colocalization were analyzed using ImageJ 1.41 with the 
Colocalisation plug-ins (Lachmanovich et al., 2003). Consistent with our previous studies, we 
found no contribution of autofluorescence at the same wavelengths used for analyses of either 
BODIPY or Alexa.  
 
Arterial LpL and cell localization and quantification  
Arterial LpL content was assayed using immunohistochemical or immunofluorescent 
staining.  For all procedures, sections were washed and treated with 4% normal goat serum 
(Sigma-Aldrich) to block non-specific background staining before antibody application.  
Sectioned aortas from L1 and wild type mice were analyzed for arterial LpL by 
immunohistochemistry. This was performed by using a rabbit polyclonal anti-human LpL 
antibody (1:20) with a biotinylated anti-rabbit secondary antibody, followed by ExtrAvidin 
Alkaline Phosphatase in situ for measuring substrate products (Sigma Rabbit ExtrAvidin 
Alkaline Phosphatase kit, Sigma-Aldrich) as described previously (Feng et al., 2003). The 
microscope settings for LpL were the same as previously described (Seo et al., 2005). Captured 
images were measured for LpL staining intensity in the arterial wall using ImageJ similarly as 
described above for quantification of fluorescence intensity. Results from at least 10 different 





In separate analyses, arterial LpL content was assayed by immunofluorescent staining. 
Before antibody application, aorta sections were processed as described above. Sections were 
incubated with a primary anti-LpL antibody (raised in rabbit) for 24 h at 4 °C, or for 2 h if 
incubated at room temperature. Sections were then rinsed and incubated for 1 h in goat anti-
rabbit IgG conjugated with Alexa Fluor 647 followed by incubation with a cell nucleus marker-
SYTOX Green for 30 min. After several washes in PBS, stained sections were mounted and 
coverslipped. Fluorescence in the arterial wall was analyzed using a laser scanning confocal 
microscope (LSM-510 META) equipped with an image-captured device at x10 and x40 
magnifications as described above. Labeled nuclei and LpL were visualized by excitation at a 
wavelength of 488 nm with a 505 to 550 nm band-pass emission filter and by excitation at a 
wavelength of 633 nm with a 638 nm low-pass emission filter, respectively. 
To quantitate arterial immuno-stained LpL in each optical section, regions of interests 
(ROI) were defined based primarily on the location of cell nucleus staining (SYTOX Green), 
which highlights arterial structure. All LpL markers within each ROI were semi-automated 
counted using ImageJ (Abramoff, 2004). Each optical section was adjusted for proper threshold 
and background subtractions to separate the correct signal from background. Particle sizes 
ranging from 90 to 255 Grey were counted using the Analyze Particles function of ImageJ. Each 
group consisted of three to four mice. For each artery sample, 10–20 sections were prepared and 
analyzed. Possible clusters of LpL signals are also determined by the Analyze Particles function, 
because it provides options for segmentation when studying the circularity and size of particles.  
The colocalization of arterial LpL with aortic cells was examined by IFC similar to the 
process described above. Artery sections were co-incubated with primary chicken anti-LpL, rat 





the 1 h incubation of the mixture of corresponding secondary antibodies of Alexa 647 anti-
chicken IgG, Alexa 488 anti-rat IgG and Alexa 546 anti-rabbit IgG. Fluorescence in the arterial 
wall was analyzed using a laser scanning confocal microscope (LSM-510 META). An argon 
laser (488 nm) and
 
two helium–neon lasers (543 nm and 633 nm) were used for the excitation of 
Alexa 488, 546, and 647, respectively.
 
 We have developed a method of quantifying 
colocalization of the confocal fluorescence of LpL and aortic cell. In brief, the patterns of Alexa 
488, 546 and 647 three channel colocalization were analyzed by a threshold-based overlap 
analysis – a binary test of whether the three signals occur in the same or in different regions 
using ImageJ 1.41 with the Colocalisation (Lachmanovich et al., 2003). The percentage 
colocalization of aortic macrophages or EC with LpL was quantitated using ImageJ as the 
percentage of macrophages or EC containing pixels that also contained LpL signals. 
Arteries from the aortic root to the tracheal artery from L1 mice and wild type littermates 
were pooled and homogenized for Western blot analyses for LpL. A total of 30                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
μg of protein from mouse artery homogenates (n=3–5) were separated with 8% nongradient 
SDS-PAGE and transferred to Duralon membranes for immunoblot analyses for LpL (1:500). 
After antibody applications, horseradish peroxidase conjugated anti-rabbit IgG were detected 
using an enhanced chemilumescent substrate (SuperSignal, Pierce Biotechnology, Inc.) and 
exposed to X-ray films according to the manufacturer‟s instructions. Three separate Western 
blots were performed from different animals. Bands corresponding for each protein were 
measured by densitometry and normalized for β-actin levels for each sample. Results were 







Student‟s t-tests of group means were used to compare endpoints and ANOVA was used 
to evaluate potential interactions between diets. Statistical significance was determined at the 

























Diet effects on body weight and plasma lipid profiles 
L1 mice were fed either a high fat diet enriched with SAT or n-3, or standard rodent 
chow as a control over a 12-week period. Mice fed the SAT or n-3 diets showed similar weight 




   
 
Despite the similar weight gain seen in SAT- and n-3-fed mice, the effects of diet on 
modulating plasma lipids were markedly different (Figure 3-2). After the 12-week feeding 
Figure 3-1: Effects of diet on body weight in L1 mice. 
Effects of diet on mouse body weight in L1 mice fed a chow (■), SAT (▲) or n-3 (●) diet 
for 12 weeks. Each point represents the mean of 10 mice ± SD. * and 
# 
denote significant 







period, L1 mice on the chow diet were hyperlipidemic; plasma FFA and TG levels were 
significantly higher than those we had previously reported for a non-diabetic mouse model (i.e., 
C57BL/6) (Chang et al., 2009) (Table 3-1). As shown in Figure 3-2, SAT diets further increased 
these already abnormal plasma lipid parameters in L1 mice; plasma FFA and TG levels were 
three- to six-fold elevated, respectively, compared with the chow diet. On the other hand, n-3-fed 
L1 mice had no or a much smaller increase in plasma FFA and TG levels compared with other 
groups throughout the study (p< 0.05).  
SAT diet feeding led to a  two-fold or greater increase in plasma total cholesterol levels 
than did chow (p<0.05), whereas the cholesterol levels of n-3-fed mice remained constant toward 
the end of the feeding period and were similar to those of chow-fed mice (Figure 3-2C). These 
findings were of interest, since changes in plasma total cholesterol levels were similar between 
mice fed the n-3 diets, which contained high amounts of cholesterol (0.2%, w/w), and mice fed 
the chow diets containing much less cholesterol (0.02%, w/w). Of note, L1 mice on all diets had 
higher levels of all lipids compared with values we had previously reported in C57BL/6 mice 
(Chang et al., 2009) (Table 3-1). 
A high fat diet can induce insulin resistance in mice (Merat et al., 1999). To distinguish 
between the effects of specific dietary FA on the markers of insulin resistance, SAT and n-3 diets 
used in our studies were isocaloric but with higher fat content (42% of total calories) than normal 
rodent chow (21% of total calories). SAT fed L1 mice had marked hyperglycemia and 
hyperinsulinemia (Figure 3-3) when compared with non-diabetic C57BL/6 mice (unpublished 
data). n-3-fed L1 mice had glucose and insulin levels relative to chow-fed L1 mice. Chow-fed L1 





al., 2004). These findings suggest that qualitative rather than quantitative differences in dietary 
FA are more important in influencing blood glucose levels and plasma lipid levels.  
To further characterize plasma lipoprotein profiles in these L1 mice that were fed with 
these different diets, changes in plasma lipoprotein distributions were analyzed using FPLC 
(Figure 3-4). In accordance with the increase in plasma TG levels, VLDL fractions were 
increased substantially in SAT-fed mice; four-fold greater than those in chow-fed mice group 
(Figure 3-4A). By contrast, n-3-fed mice had lower VLDL fractions. Of note, SAT diets also 












































































Figure 3-2: Plasma lipids in L1 mice during the feedings. 
Plasma lipid profiles of L1 mice fed a chow (■), SAT (▲) or n-3 (●) diet. Blood samples were 
determined weekly for free fatty acids (FFA), triglyceride (TG) and total cholesterol (T-Chol) 
levels as described in Methods. The results are expressed as the mean ± SD (n>8). 
*
, p<0.05, chow 
vs. SAT or n-3; 
#











Four-week-old mice fed chow, SAT or n-3 diets for 12 weeks (n>10). Mouse body weight was 
measured and blood samples were collected and determined for free fatty acids (FFA), total cholesterol 
(T-Chol) and triglyceride (TG) levels as described in Methods. The  results are expressed as the 
mean±SD. Values shown for C57BL/6 mice were previously reported in reference 6.
C57 BL/6 L1
Chow SAT n-3 Chow SAT n-3
Body weight (g) 23.39±1.00 26.70±0.86 24.12±0.90 31.5±0.88 33.56±0.53 34.3±1.78
FFA (mM) 0.42±0.26 0.82±0.20 0.25±0.10 0.73±0.15 1.04±0.10 0.60±0.07
T-Chol (mg/dl) 67.52±3.06 102.24±11.10 111.78±11.24 78.36±11.91 146±20.95 77.50±34.68
TG (mg/dl) 56.65±5.84 130.96±6.97 21.39±4.68 196.06±65.11 351.77±119.41 76.51±63.05
Table 3-1: Plasma lipid levels of C57BL/6 and L1 mice fed a chow, SAT or n-3 diet. 
Four-week-old mice fed chow, SAT or n-3 diets for 12 weeks (n>10). Mouse body weight and 
plasma FFA, T-Chol and TG levels were measured as described in Methods.The results are 































Figure 3-3: Effects of diet on blood glucose and insulin levels in L1 mice. 
Blood glucose and insulin levels were measured at the end of feedings. * SAT vs. chow; ** SAT 













Diet effects on arterial LDL uptake 
We examined the effects of these dietary FA on arterial LDL uptake and SU in the L1 
model. We used fluorescent-labeled LDL to directly examine LDL uptake and LDL-CE 
deposition in the arterial wall. At baseline, before introduction of any experimental diets, L1 
mice exhibited higher levels of LDL-CE uptake than their wild type littermates (Figure 3-5A). 














































Figure 3-4: Plasma lipid profiles in L1 mice fed a chow, SAT or n-3 diet. 
Triglycerides (TG; A) and cholesterol (Chol; B) were determined for each fraction after separating 








the arterial wall and by more green fluorescence in the overlay when compared with wild type 
littermates (p<0.05) (Figure 3-5B). 
Figure 3-6 shows the effects of different dietary FA on LDL uptake and deposition in L1 
mouse aortas. Compared with chow fed L1 mice, the overlay image of SAT-fed mice showed 
disproportionably higher LDL-CE delivery relative to apoB, indicating SU. By contrast, with the 
reduced uptakes of LDL-apoB and LDL-CE, similar amount of apoB and LDL-CE localized in 
the luminal side in n-3-fed mice. Moreover, there was a reduced infiltration of LDL in n-3-fed 
mice compared with chow- or SAT-fed mice (Figure 3-6A). These findings are consistent with 
our previous reports on C57BL/6 mice (Chang et al., 2009); SAT diets increased LDL uptake 
and SU (p<0.05), whereas n-3 diets consistently abolished arterial LDL SU, and the effects were 



























Figure 3-5: LDL and LDL-CE uptake in WT and L1 mice. 
Comparison of arterial LDL-CE (BODIPY) and LDL-apoB (Alexa) uptakes in wild type littermates 
(WT) or L1 mice (A). Merged two-channel images (right panel) were used to assess colocalization of 
Alexa and BODIPY with yellow fluorescence indicating colocalization.  Magnification is 20x. (B) 
Ratios of arterial uptake of total LDL-CE to whole LDL particle uptake determined for L1 mice and 








































































Figure 3-6: Effects of diet on fluorescent LDL-CE and apoB uptakes in aortas. 
Fluorescent LDL-CE (BODIPY) and -apoB (Alexa) uptakes in aortas (A). (B) Ratios of arterial uptake 
of total LDL-CE to whole LDL particle uptake determined for each diet group (mean ± SE).  Ratios 
were normalized to the same unit area for each diet. A ratio >1 indicates SU (dotted line).  *, p<0.05, 









Dietary fat changes arterial LpL levels and distribution 
We and others have demonstrated that LpL associates the binding of lipoproteins to cell 
surface PG, especially HSPG, to accelerate cellular uptake of LDL and other lipoproteins (Seo et 
al., 2000, Rumsey et al., 1992, Williams et al., 1992). Our previous studies showed that increased 
LpL in arterial wall was linked to increased arterial LDL uptake and SU in C57BL/6 and apoE 
knockout mice (Seo et al., 2005).  
Therefore, we examined arterial LpL expression levels by immunohistochemistry and 
IFC in our insulin-resistant L1 mouse model. There was a marked increase in arterial LpL levels, 
as indicated by more reddish-brown staining (Figure 3-7A), in L1 mice than in wild-type 
littermates. Similar findings of increased LpL were observed by Western blot analysis of pooled 
artery homogenates (Figure 3-7B), where densitometric analyses of arterial LpL normalized for 
β-actin showed ~20% increase in L1 compared with wild-type mice when both mouse groups 
were fed the chow diets (L1, 1.28±0.03  vs. wild type, 1.07±0.03 , n=3–5, p<0.05).   
Effects of diet on arterial LpL levels in L1 mice were also examined (Figure 3-7C). 
Immunofluorescent staining of arterial LpL was markedly increased in SAT fed mice when 
compared with chow-fed mice (SAT/chow ratios, 1.39±0.06, n=3, p<0.05). By contrast, n-3-fed 
mice showed very low levels of arterial LpL (Figure 3-7C), and this parallels the decrease of 














Colocalization of LpL and aortic macrophages  
Previous studies have shown that dietary saturated FA increase macrophage-derived LpL 
mass, activity and mRNA levels (Li et al., 2002, Hayek et al., 2005). Our preliminary data (not 
shown) on C57BL/6 mice show that SAT diets but not n-3 diets increased the number of arterial 
Figure 3-7: Effects of insulin resistance and diet on arterial LpL levels. 
Effects of insulin resistance and diet on arterial LpL levels. (A) Immunohistochemical staining of 
arterial LpL. Reddish-brown staining shows the presence of LpL. (B) Representative images of 
Western blots for LpL (~55 kDa) from pooled mouse artery homogenates (n=3) (C) 
Immunofluorescence of arterial LpL from mice fed a chow, SAT or n-3 diet. Magnifications are 
















macrophages, which could contribute to increased LpL levels. Thus, correlations of arterial LpL 
levels and macrophages were investigated in the L1 mouse model by IFC (Figure 3-8A). 
Counter-staining of LpL, EC and macrophages showed that the presence of LpL was linked to 
arterial medial macrophages (Figure 3-8B). More than 60% of LpL and macrophages colocalized 
in SAT fed L1 mice (Figure 3-8C). In n-3-fed mice, there was almost no staining for LpL or 
macrophages in the arterial media; LpL was mostly at the intima, with some in the adventitial 
regions (Figure 3-8C). Thus, increases in arterial LpL are linked to increases in medial 

























Figure 3-8: Arterial macrophages and LpL in the aorta.  
(A) Representative images of chow-, SAT- or n-3-fed L1 mouse aortas stained for endothelial cells 
(EC, blue), LpL (green) and macrophages (red). Magnification is 40x. (B) Immunofluorescence of 
macrophages quantitated for each group (n>3). (C) Percent of macrophages colocalizing with LpL 







Atherosclerosis, a major contributor to CVD, can be modulated by dietary fat intake 
patterns, insulin resistance, and type 2 diabetes (Hu et al., 2003). Dietary saturated fats and 
insulin resistance both promote CVD; dietary n-3 fats prevent atherosclerosis and lower CVD 
morbidity and mortality (Breslow, 2006, Deckelbaum et al., 2006, Mozaffarian and Rimm, 2006, 
Wang et al., 2006). In the studies described here, we examined the effects of dietary saturated or 
n-3 FA on plasma lipid, glucose and insulin levels and LDL cholesterol deposition in the arterial 
wall in L1 mice - an insulin resistant mouse model. Although hepatic insulin signaling has not 
been disrupted in these L1 mice, compared with our earlier studies in C57BL/6 mice (Chang et 
al., 2009), L1 mice exhibited abnormal plasma lipid profiles, including elevated plasma FFA, TG 
and different patterns of plasma lipoprotein distribution. These differences were further 
exacerbated by SAT feedings. On the other hand, the n-3 diets reduced all plasma lipids, 
including cholesterol, in L1 mice. Several findings from L1 mice in the current studies are 
different from the previous reports on non-diabetic C57BL/6 mice (Chang et al., 2009). Our diet 
studies on C57BL/6 mice showed similar increases of plasma total cholesterol levels in both 
SAT and n-3 fed groups, presumably because of  the high cholesterol content in both diets (0.2%, 
w/w, compared with 0.02%, w/w,  in the chow diet) (Chang et al., 2009). In L1 mice fed similar 
diets, plasma total cholesterol levels were only significantly increased in SAT-fed mice, not in n-
3-fed mice. Compared with our previous studies using C57BL/6 mice, in which there was no 
VLDL fraction in chow-fed mice, L1 mice fed the same chow diets had significant VLDL 
fractions. However, the VLDL fraction essentially disappeared in L1 mice that were fed the n-3 
diets. Reduced TG levels in n-3-fed L1 mice could result from the reduced plasma TG-rich 





Moreover, the results on weight change of L1 mice are different from the similar diet studies on 
C57BL/6 mice (Chang et al., 2009). SAT- and n-3-fed L1 mice had similar weight gain, 
however, substantially less weight gain was seen in C57BL/6 mice fed the n-3 diets compared 
with mice fed the SAT diets. Regardless of the fat content in each diet, our data indicates that L1 
mice were more prone to diet-induced obesity. 
Both SAT- and n-3-fed groups had elevated plasma insulin levels, but n-3-fed mice had 
blood glucose levels similar to chow-fed mice. We have not examined β-cell functions in the 
current studies However, as characterized in the previous studies (Okamoto et al., 2004), L1 
mice have islets of normal size with normal architecture and a moderate reduction in β-cell mass. 
After 12 weeks of feeding, n-3-fed L1 mice displayed hyperinsulinemia with relatively normal 
glucose levels. In contrast, SAT fed mice had substantially higher glucose levels but lower 
insulin levels, suggesting the progressive deterioration of compensatory insulin secretion by 
pancreatic β-cells. Thus, it is possible that the SAT fed mice with persistent severe 
hyperinsulinemia and hyperglycemia have proceeded to β-cell failure. By contrast, n-3 FA may 
inhibit processes that are important to atherosclerosis progression even with ongoing 
hyperinsulinemia. 
Loss of insulin signaling in vascular EC can impair endothelium-dependent vasodilation 
and increase VCAM-1 expression to accelerate atherosclerosis in apoE-/- mice (Rask-Madsen et 
al., 2010). In our studies, L1 mice do not develop accelerated atherosclerosis spontaneously, 
which may be consistent with the hypothesis that excessive, rather than reduced insulin signaling 
is atherogenic (Han et al., 2006, Han et al., 2009) or with the alternative but not mutually 





versus lipid metabolism (Kim et al., 2000, Haeusler and Accili, 2008). More studies are needed 
to elucidate the underlying mechanisms.  
Recent studies from Han et al. (Han et al., 2009) reported that when L1 mice were 
backcrossed with LDLR-/- mice on a uniform C57BL/6 genetic background, they were protected 
from atherosclerosis and showed reduced VLDL/LDL levels and hepatic VLDL secretion. Still, 
these mice were hyperinsulinemic. Furthermore, the reduced levels of hepatic insulin receptors 
found in these double knockout mice led to the reduced insulin signaling via IRS1/PI3K and 
reduced levels of Akt phosphorylation and its downstream targets, including reduced expression 
of lipogenic genes and decreased VLDL secretion. This is of interest, because our L1 mice have 
human insulin receptor transgene expressed in liver similar to that of those in the study by Han et 
al. The distinguishing features between the L1 mice used by Han and those in our study are our 
findings of hyperglycemia and dyslipidemia with significantly higher levels of VLDL and LDL. 
Our L1 mice were maintained on a mixed genetic background, which might explain some of the 
differences in the predisposition to diet-induced hyperglycemia; their genetic makeup contains 
chromosomes derived from 129SV, C57BL/6 and FVB genomes.  We have not characterized 
hepatic insulin signaling pathways in these L1 mice; but we have found increased liver TG in 
these L1 mice. When these mice were fed the SAT diets, the number and size of liver lipid 
droplets further increased when compared with chow-fed L1 mice, but the n-3 diets markedly 
reduced hepatic lipid accumulation (data not shown).    
The macrophage has emerged as an important player in the pathogenesis
 
of both 
atherosclerosis and insulin resistance (Li et al., 2002, Hayek et al., 2005). Of interest, recent 
studies have suggested that saturated FA induce macrophage inflammation through the activation 





et al., 2003c, Lee et al., 2004, Kim et al., 2007, Schwartz et al., 2010). In addition, TLR4-
dependent activation of NADPH oxidase (NOX) causes both inflammation and oxidative stress, 
which contributes to arterial cell injury (Maloney et al., 2009). Our preliminary data on C57BL/6 
mice shows that the SAT diets but not the n-3 diets increased the number of arterial macrophages 
(Seo T, Chang CL, Deckelbaum RJ, unpublished data). The accumulation of macrophages in the 
arterial wall triggered by SAT diets can contribute to atherogenesis by secreting pro-
inflammatory mediators. Furthermore, our in vitro studies show that saturated palmitic acid 
promoted inflammation in cultured murine macrophages by increasing mRNA gene expression 
levels of pro-inflammatory cytokines, such as IL-6, but that n-3 EPA decreased these (Jung UJ, 
Chang CL, Deckelbaum RJ, unpublished data). Furthermore, in our in vitro studies, LpL mRNA 
expression and protein levels were increased by saturated palmitic acid but attenuated by EPA.  
In the current studies, the results on colocalization studies of LpL and macrophages in L1 
mice with different diets suggest that increased LpL levels in SAT-fed mice were associated with 
a increased number of aortic macrophages. Of note, LpL itself can augment vascular dysfunction 
in the setting of inflammation. LpL directly induces TNF-  gene expression and synergizes with 
interferon-  in the stimulation of macrophage nitric oxide synthase expression and endothelial 
NOX (Wang et al., 2008, Renier and Lambert, 1995). LpL-induced TNF-  expression can 
further increase ICAM/VCAM, E-selectin and expressions of other pro-inflammatory genes in 
vascular cells (Kota et al., 2005). In addition, LpL has been proposed to function as a monocyte 
adhesion protein on EC and in subendothelial matrix (Fisher et al., 2003, Li and Renier, 2007). 
Taken together, we hypothesize that, whereas saturated FA stimulate inflammation in vascular 





macrophages as well as LpL and pro-inflammatory cytokine production in atherosclerosis-
susceptible sites. Hyperglycemia as documented in these L1 mice was exacerbated by SAT diets 
but not n-3 diets, which might lead to advanced glycation end products. These in turn could 
stimulate macrophage LpL gene expression and secretion (Beauchamp et al., 2004), another 
potential pathway that would contribute to the increased aortic LpL levels.  
In the current studies, similar to others, we suggest that LDL-cholesterol accumulation is 
one key pathogenic event and a requirement for lesion development in early atherosclerosis 
progression; however, other factors can affect binding uptake and the flux of the lipoproteins to 
the artery. For example, the changes in lipid levels and lipoprotein profiles associated with the 
SAT diet could affect arterial LDL uptake and deposition, i.e., it is possible that the increases of 
both VLDL and FFA accelerate LDL accumulation in the arterial wall. Another possibility that 
might influence LDL accumulation in the arterial wall is the changes in vascular permeability 
(Rutledge et al., 1997).     
We suggest that feeding mice with high SAT diets parallels the conditions that increase 
arterial LDL delivery and CE deposition in humans. However, because of SAT diets also 
enhance diabetes in mice; this could confound interpretation of some of our findings. The 
potential relative contributions of insulin resistance-induced hyperglycemia and dyslipidemia are 
not fully separated or defined in our studies. In mouse models (e.g., LDLR-/- mice), 
hyperlipidemia can be exacerbated by high saturated fat feeding with the onset of hyperglycemia 
and accelerated atherogenesis. Hyperglycemia has been suggested to have an independent role in 
atherogenesis (Renard et al., 2004). Studies by Gerrity et al. have shown that fat-fed diabetic pigs 





al., 2001). Consumption of a cholesterol-free diet by LDLR-/- mice with diabetes induced by -
cell-directed viral antigen resulted in hyperglycemia without changes in plasma lipids and 
lipoproteins, but with more rapid atherosclerosis (Renard et al., 2004). Still, progression of 
atherosclerosis is mainly initiated by a high-fat diet with the addition of dietary cholesterol 
independent of hyperglycemia (Mazzone et al., 2008, Merat et al., 1999).  
In summary, total LDL uptake and SU can be an important contributor to accelerated 
arterial LDL-CE uptake in insulin resistant L1 mice. Moreover, in L1 mice, similar to other 
mouse models, cholesterol delivery to the arterial wall is modified by the type of dietary fat, in 
part, through changes in arterial LpL levels. Whereas a SAT diet increased total LDL-CE uptake 
and SU, an n-3 diet inhibited these pathways, which are important to atherosclerosis progression 
in L1 mice. Because L1 mice, and also C57BL/6 mice as described in Chapter 1, did not develop 
identifiable atherosclerotic lesions, we then asked whether n-3 FA can modulate the extent and 














CHAPTER 4 : EFFECTS OF N-3 FA ON DEVELOPMENT OF 
ATHEROSCLEROSIS AND ARTERIAL LPL LEVELS AND 
DISTRIBUTION IN LDLR-/- MICE 
 
SUMMARY 
Objectives- Our previous studies have demonstrated that dietary saturated FA increase arterial 
LpL levels and promote arterial LDL deposition in the early development of atherosclerosis. In 
contrast, n-3 FA rich diets decrease arterial wall LDL deposition and LpL levels. We now 
questioned whether n-3 FA can counteract SAT-induced pro-atherogenic effects in a well-
established animal model for atherosclerosis, LDLR-/- mice. We examined the effects on 
markers for atherosclerosis development of replacing SAT with increasing amounts of n-3 FA in 
high-fat, saturated FA-rich diets.  
Methods and Results- LDLR-/- mice were fed a regular rodent chow diet or high fat diets 
enriched in SAT, n-3 FA, or a combination of both SAT and n-3 in the ratios of 3:1 (S:n-3 3:1) 
or 1:1 (S:n-3 1:1). Mice fed SAT diets were hyperlipidemic and developed advanced 
atherosclerosis. By contrast, n-3 diets decreased plasma lipids, especially cholesterol, and 
markedly reduced atherosclerosis development. Diets that contained as little as 25% of n-3 FA 
(S:n-3 3:1) improved LDLR-/- mouse lipid profiles and slowed the progression of 
atherosclerosis. Arterial LpL and macrophage levels were increased in LDLR-/- mice after SAT 
feeding but then decreased with gradual replacement with n-3 FA.  
Conclusion- Replacement of SAT with n-3 FA decreases plasma plasma lipids, including 







Dietary FA affect arterial lipid deposition. Our previous studies have demonstrated that 
increased arterial LpL levels induced by dietary saturated FA promote arterial LDL deposition 
before the development of atherosclerosis. By contrast, n-3 FA-rich diets decreased arterial wall 
LDL deposition and LpL levels. However, the role of dietary FA in atherogenesis is complex; 
much of our information about their roles was derived from studies with the diet enriched in SAT 
only, or in n-3 only. Fat intake in humans usually includes both SAT and n-3 FA; little is known 
about the effects of dietary intake of n-3 FA with concomitant high SAT intake on arterial lipid 
deposition and atherosclerosis development.  
Evidence suggests that energy replacement of SAT by PUFA decreases risk factors of 
CVD by decreasing total cholesterol, LDL cholesterol and TG (St-Onge et al., 2007) and 
inflammatory markers (Zhao et al., 2004). Replacing SAT with a combination of n-3 and n-6 FA 
may decrease the risk for CVD even more than n-6 alone (Ramsden et al., 2010). n-3 FA alone in 
our model systems, both in vivo and in vitro, have been shown to decrease arterial LDL uptake 
and retention, inflammation and atherosclerosis (Jung et al., 2008, Sudheendran et al., 2010, De 
Caterina, 2011). However, it is not clear whether n-3 FA could counteract the pro-atherosclerosis 
effects mediated by SAT.  
The C57BL/6 mouse model that we have used to study the effects of dietary FA on 
arterial LDL uptake and LpL levels has some limitations. For example, they do not develop 
atherosclerosis.  In response to the SAT diet, C57BL/6 mice develop mild hypercholesterolemia 
with VLDL accumulation and LDL deposition located strictly in proximal aorta (Paigen et al., 
1987, Seo et al., 2005). To study the pathogenesis of atherosclerosis, this human disease has been 





mice (Kowala et al., 2000). Although mice are the most cost-effective model, they respond 
poorly to cholesterol diets and only develop small fatty streaks in the aortic root (Paigen et al., 
1985). The use of gene knockout has created the mouse strain of LDLR-/- mice with altered 
plasma lipoprotein profiles and susceptibilityto atherosclerosis. LDLR-/- mice are mildly 
hypercholesterolemic because of the absence of hepatic LDLR which prolongs the plasma half 
lives of VLDL and LDL (Ishibashi et al., 1993). However, when LDLR-/- mice are fed an 
atherogenic diet, they became severely hypercholesterolemic and developed aortic 
atherosclerosis and subcutaneous xanthomas  (Ishibashi et al., 1994). Therefore, we chose to 
study in LDLR-/- mice the affects of dietary FA at different stages and severity of atherosclerotic 
lesion formation.  
To study the regulatory effects of specific dietary FA and the combination of FA on the 
progression of atherosclerosis and arterial LpL levels and localization, LDLR-/- mice were fed a 
regular mouse chow diet or diets enriched in either SAT, n-3, or a combination of both SAT and 
n-3 in the ratios of 3:1 (S:n-3 3:1) or 1:1 (S:n-3 1:1). The data demonstrated that as little as 25% 
of n-3 FA in total dietary fat intake offset the adverse effects mediated by SAT. n-3 diets 
improved mouse plasma lipid profiles, especially cholesterol levels, and decreased 
atherosclerosis in LDLR-/- mice when compared with SAT diets. LpL was found abundantly and 
mainly colocalizing with macrophages in atherosclerotic lesions among each feeding group, 
suggesting its role in atherosclerotic plaque progression. In proximal aorta, LpL was associated 









Nine-week-old male LDLR-/- mice were purchased from Jackson Laboratory. After 1-
week of acclimatization, a total of 75 mice were assigned randomly to 5 groups of 15 animals 
each. LDLR-/- mice were fed a low-fat chow diet or a high-fat diet enriched in either saturated 
fats (Harlan Tekland, TD08081), n-3 fats (TD07500), or in the combination of SAT and n-3 in 
the ratios of 3:1 or 1:1 (TD08533 and 08532) for 12 weeks. These diets contained 42.5 g fat and 
2 g cholesterol per 100 g diet and varied only in lipid composition (Table 4-1).  The food 
consumption of mice was monitored daily, and their body weight was measured weekly. All 









SAT: n-3  
1:1 
n-3 
% of SAT  0 100 75 50 0 
% of MUFA 0 0 0 0 0 
% of n-6 PUFA 100 0 0 0 0 
% of n-3 PUFA 0 0 25 50 100 
% kcal from fat 16.4 42.5 42.5 42.5 42.5 
% kcal from carbohydrate 65.7 39.7 39.7 39.7 39.7 
% kcal from protein 17.9 17.9 17.9 17.9 17.9 
Cholesterol w/w 0.02g 0.2 g 0.2 g 0.2 g 0.2 g 
 





Plasma lipid analyses 
 Fasting mouse plasma was collected and measured for levels of FFA (NEFA C 
kit, Wako, Neuss, Germany), TG and total Chol  (Roche Diagnostics, Indianapolis, IN) 
according to the manufacturer‟s procedures as previously detailed (Qi et al., 2002).  Blood was 
collected by retro-orbital venous plexus puncture of anesthetized mice at 4- and 8-wk and by 
cardiac puncture at the end of 12-wk feeding (Chang et al., 2010). 
 
Morphormetric analyses of atherosclerosis 
At the end of the feeding periods, mice were euthanized and perfused extensively with 
nuclease-free RNAse inhibitor (Sigma-Aldrich) in PBS. Aortas were dissected from the middle 
of left ventricle to the iliac bifurcation using a stereoscopic zoom microscope. Dissected aortas 
were fixed in 4% paraformaldehyde on ice for 2 h followed by the equilibration in 30% sucrose 
solution at 4°C overnight. The equilibrated samples were cut in the descending aorta, and the 
proximal samples containing the aortic valve and arch were positioned vertically and embedded 
in Tissue-Tek OCT (Sakura Finetek). Embedded samples were first frozen on dry ice and then 
stored in a -80°C freezer. 
Embedded samples were sectioned with a cryomicrotome. Sections were collected when 
the presence of aortic sinus was reached. We collected 9-μm thick sections and sequentially 
placed them onto six slides. Each of the six slides had six step sections that were 54 μm apart 
over a 324-μm area. A total of 18 slides were collected until the length of aorta that was 
sectioned was ~ 900 μm, spanning the aortic valve, ascending aorta, arch and the beginning of 
the descending aorta.  Every first and seventh slides from each mouse was stained with H&E or 





were measured using ImagePro imaging software and Photoshop. The amount of aortic lesion 
formation in each animal was measured as a total lesion area per aorta from the point at which all 
three aortic valve leaflets
 




The localization of arterial LpL with aortic cells was examined by IFC similar to the 
process as described in Chapter 2 and 3. Artery sections were co-incubated with primary chicken 
anti-LpL, rat anti-EC and rabbit anti-macrophage antibodies for 24 h at 4°C, followed by 1-h 
incubation of the mixture of corresponding secondary antibodies of Alexa 647 anti-chicken IgG, 
Alexa 488 anti-rat IgG, and Alexa 546 anti-rabbit IgG. Fluorescence in the arterial wall was 
analyzed using a laser scanning confocal microscope (LSM-510 META). An argon laser (488 
nm) and
 
two helium–neon lasers (543 nm and 633 nm) were utilized for the excitation of Alexa 




Quantitative Real-time PCR  
Total RNA was isolated from a mouse proximal aorta with TRIzol reagent (Invitrogen). 
Single strand cDNA was synthesized from RNA using SuperScript reverse transcriptase 
according to the manufacturer‟s instructions (Invitrogen). Quantitative real-time PCR was 
carried out on an iCycler (Bio-Rad) using SYBR PCR kit (Applied Biosystems). Results were 
analyzed by comparing the threshold crossing (Ct) of each sample after normalization to control 





each mRNA using the formula 2
–ΔCt
. All real-time PCR reactions were carried out at least twice 




Student‟s t-tests of group means were used to compare endpoints, and ANOVA was used 
to evaluate potential interactions between diets. Statistical significance was determined at the 






Primer Forward Primer  Reverse Primer 
TNF-α CCAGACCCTCACACTCAGATCA CACTTGGTG GTTTGCTACGAC 
MCP-1 AACTGCATCTGCCCTAAG AAGGCATCACAGTCCGA 
CD68 CTTCCCACAGGCAGCACAG AATGATGAGAGGCAGCAAGAGG 
IL- 6 AACCACGGCCTTCCCTACTTC GCCATTGCACAACTCTTTTCTCAT 
VCAM-1 CCCAAGGATCCAGAGATTCA TAAGGTGAGGATGGCATTTC 
MR CATGAGGCTTCTCCTGCTTCTG TTGCCGTCTGAACTGAGATGG 
IL-10 ATTTGAATTCCCTGGGTGAGAAG CACAGGGGAGAAATCGATGACA 
LpL GAGGAATCTAATGGCCCATAGC GGAACTCACTCTGTAAACCAGG 
GAPDH TGCAGTGGCAAAGTGGAGAT TTGAATTTGCCGTGAGTGGA 
 






Characterizations of LDLR-/- mouse body weight and plasma lipid levels in response to dietary 
FA  
Mice lacking of the LDL receptor were fed a regular rodent chow diet or a diet enriched 
in only SAT, n-3 FA, or a combination of both SAT and n-3 in the ratios of 3:1 (S:n-3 3:1) or 1:1 
(S:n-3 1:1) for 12 weeks (n=15). All groups of mice showed similar rates of weight gain during 
the feeding period. At the end of feeding, there were significant increases in body weight in mice 
fed the SAT diet and the S:n-3 3:1 diet compared with chow (p<0.05, Figure 4-1). Among 
groups fed a diet containing n-3 FA, mice fed n-3 had the least weight increase when compared 
with S:n-3 3:1 or 1:1 (p<0.05). The average daily intake among each feeding group was similar.  
LDLR-/- mouse plasma lipid profiles were determined at the end of feedings. Consistent 
with the previous findings in C57BL/6 mice, SAT diets led to a >70% increase in plasma FFA 
and a two-fold increase in TG levels (p<0.05, Figure 4-2A and 4-2B) in LDLR-/- mice when 
compared with the chowdiets. The presence of n-3 FA in S:n-3 3:1 and 1:1 diets decreased FFA 
and TG in mice to levels similar to that of chow fed mice (Figure 4-2A and 4-2B). By contrast, 
n-3-fed LDLR-/- mice had at least a 40% decrease in plasma FFA and ~70% lower TG than that 
of chow-fed mice (p<0.05, Figure 4-2A and 2B). Chow-fed LDLR-/- mice had elevated plasma 
cholesterol levels compared with wild-type C57BL/6 mice (Chang et al., 2009). SAT-only 
feedings resulted in severe hypercholesterolemia in LDLR-/- mice. Mice fed the S:n-3 3:1 had 
increased cholesterol levels,  but mice fed the S:n-1 1:1 diets had no increase or much less of an 
increase in plasma cholesterol when compared with chow-fed mice. n-3 diets further decreased 
plasma cholesterol levels in LDLR-/- mice than did chow diets (Figure 4-2C). Note that the 





w/w, in the chow diet). Therefore, we suggest that n-3 FA are effective in reducing plasma lipids, 
including cholesterol, in mice prone to atherosclerosis, such as LDLR-/- mice, even when on 

































Figure 4-1: Effects of diet on body weight in LDLR-/- mice. 
Each point represents the mean ±SE of 15 mice. *, p<0.01. SAT/S:n-3 3:1 vs. chow; #, p<0.01, SAT/ 






























































Figure 4-2: Plasma lipid profiles in LDLR-/- mice. 
Blood samples were determined for plasma free fatty acids (FFA), triglycerides (TG), and 
total cholesterol (Chol) at the end of 12-weeks of feeding with specific diets (mean±SE). *, 





















Effects of diet on fatty acyl composition of artery 
In our earlier studies, we demonstrated that diets modulate plasma fatty acyl composition 
(Chang et al., 2009). We now examined the changes of fatty acyl composition in mouse artery in 
LDLR-/- mice after feeding by using GLC as described in the Methods section of Chapter 2. 
Consistent with our previous studies in wild-type C57BL/6 mice (unpublished data), SAT 
significantly increased arterial saturated lauric (12:0) and myristic (14:0) acids (p<0.05). The 
additions of n-3 fats in diets markedly increased arterial EPA (20:5), DPA (22:5) and DHA 
(22:6) (p<0.05) in arteries (Figure 4-3). Note that DHA in the aorta increased much more than 


























Figure 4-3: Fatty acyl composition of artery in LDLR-/- mice. 
At the end of feedings, LDLR-/- mouse arteries were collected for measuring fatty acyl composition by 






Effects of dietary FA on atherosclerosis development 
We examined the effects of dietary FA on the progression of atherosclerotic lesion 
development in LDLR-/- mice. Lesions were examined with H&E or Oil-red-O staining on aortic 
sections at the level of the aortic valve (Figure 4-4).  In chow-fed LDLR-/- mice (Figure 4-4A), 
lipid-laden foam cells were found on the sections of the aortic valve (black arrows). Advanced 
complex plaques were observed in all SAT-fed mice, as characterized by the formation of 
necrotic cores, and a thinning fibrous cap as shown with higher magnification. By contrast, aortic 
morphology of n-3-fed LDLR-/- mice was similar to that of chow fed mice (Figure 4-4A), even 
when n-3 replacement only made up 25% of the total fat intake (data not shown). 
Chow-fed LDLR-/- mice had modest fatty streaks developing in the aortic root (Figure 4-
4B). Substantial neural lipid deposition was found in mice fed SAT-only diets indicated by 
staining of Oil-Red-O; however, small fatty streaks were found in n-3 fed mice (Figure 4-4B). 
Histological appearance of atherosclerosis in mouse aortic origin in mice fed the S:n-3 1:1 and 
3:1 diets were similar to that of chow-fed LDLR-/- mice (data not shown).  
The extent of the atherosclerosis was quantitated for each feeding group. Quantification 
of mean
 
lesion area showed significantly increased lesion development in SAT-fed LDLR-/- mice 
(p<0.05). Mice fed the S:n-3 3:1 diet had lesion development comparable with chow-fed mice. 
Mice fed the S:n-3 1:1 diet had a ~40% reduction in atherosclerosis when compared with chow-
fed mice. LDLR-/- mice fed the n-3 diets had the least atherosclerotic lesion formation (p<0.05, 






































Figure 4-4: Atherosclerotic lesion development in LDLR-/- mice after feeding. 
At the end of feeding periods, aorta of LDLR-/- mice were collected as described in Method. (A) 
Representative images of the aortic origin stained with H&E. (B) Representative images of the aortic 
origin stained with Oil-Red-O. (C) Quantitation of atherosclerosis in the aortic origin in LDLR-/- 







Aortic LpL and macrophages in LDLR-/- mice 
As described in Chapter 2, SAT diets increased, but n-3 diets decreased, arterial LpL in 
C57BL/6 mice.  In Chapter 3, we reported that LpL levels were linked to the number of aortic 
macrophages. In the current studies, LpL and macrophage localization, both at the aortic origin 
and proximal aorta, were examined in LDLR-/- mice after being fed specific diets. LpL was 
abundant in atherosclerotic lesions among each feeding group (Figure 4-5). Most LpL 
colocalized with macrophages. LpL and macrophages increased with an increase in lesion area 
(white arrow head) mass and severity of atherosclerosis. Accordingly, SAT fed mice with 
extensive lesions had the highest levels of LpL as well as macrophages in the aortic root. By 
contrast, mice fed n-3 diets had the lowest levels of fluorescence for LpL and macrophages. LpL 
and macrophages were colocalized with EC in the surface/luminal side of fatty streaks in n-3 fed 
mice (Figure 4-5). 
Proximal aortas in LDLR-/- mice were also examined for arterial macrophages and LpL 
after feedings (Figure 4-6A). LpL and macrophages in SAT fed groups increased in accordance 
with our previous studies (Figure 4-6B) (p<0.05). n-3 decreased arterial LpL and macrophages 
when compared with SAT (p<0.05). No notable difference in the amount of LpL was found in the 
proximal aortas of mice fed the S:n-3 3:1 or 1:1 diet when compared with chow-fed LDLR-/- 
mice. However, all diets containing n-3 significantly reduced aortic macrophages when 














EC LpL MΦ Merge
Figure 4-5: Effects of diet on LpL and macrophage localization at the aortic origin in 
LDLR-/- mice.  
Images shown are the colocalization of aortic EC (blue), LpL (green), and macrophages (MΦ, red) in 



































Figure 4-6: Effects of diet on arterial LpL and macrophages in proximal aorta in 
LDLR-/- mice. 
(A). Representative images of proximal artery sections stained for EC, LpL and MΦ in LDLR-/- 
mice that were fed specific diets for 12 weeks. “L” indicates lumen. (B). Immunofluorescence of 
aortic LpL (open bars) and macrophages (filled bars) quantitated for each group.  Mean±SE, n=2-












mRNA expression of aortic LpL and inflammatory markers 
mRNA gene expression levels of LpL and inflammatory markers that have been strongly 
linked to the development of atherosclerosis were examined in proximal artery homogenates of 
LDLR-/- mice. In collaboration with Dr. Claudia Torrejon, in a separate but similar set of diet 
studies in LDLR-/- mice in our laboratory, we investigated whether SAT and n-3 diets regulate 
gene expression involved in the inflammatory responses. mRNA expression of classically 
activated inflammatory markers (TNF-α, IL-6, CD68), alternative activated markers (mannose 
receptor, IL-10) and endothelial activation marker (VCAM-1) were examined in LDLR-/- mice 
after 12 weeks of feedings (Figure 4-7). SAT diets increased pro-inflammatory markers, 
including IL-6 (p<0.05), CD68 and VCAM-1, several times higher than the other feeding groups. 
All diets containing n-3 reduced the levels of these “classically activated” inflammatory markers 
to levels similar to those of chow-fed LDLR-/- mice. It is possible that mRNA levels of VCAM-
1 and IL-6 also changed proportionally to the changes in the number of aortic macrophages 
(CD68). However, the mRNA gene expression of TNF-α, mannose receptor, IL-10 or LpL was 
not affected by dietary FA in LDLR-/- mice (data not shown), which suggests an alternative 































































a b   b     ab    a    a
Figure 4-7: mRNA of arterial pro-inflammatory markers. 
Artery homogenates of LDLR-/- mice were analyzed for mRNA of VCAM-1, IL-6 and CD68 in each 
group. Data are expressed as mean±SE. Different superscripts are significantly different, p < 0.05, 







Arterial lipid deposition is the key step in initiating atherosclerosis. Our previous studies, 
in C57BL/6 and L1 insulin resistant mice, have shown that saturated fat-enriched diets increase 
arterial LDL and selective LDL-cholesterol uptakes, and that n-3-enriched diets significantly 
reduced both LDL whole particle and LDL-CL uptakes. We suggested that dietary FA play an 
important role in influencing pathways of atherogenesis in the very early stages. In the studies 
described here, we explored the effects of these dietary FA, SAT and n-3, on the extent and 
severity of atherosclerosis in a well-known mouse model of atherosclerosis, the LDLR-/- mouse 
model. When LDLR-/- mice were on high SAT diets, their plasma lipids- FFA and TG were 
markedly elevated. They were also hypercholesterolemic and had developed advanced 
atherosclerosis after 12-weeks of feeding. All diets containing n-3 reduced plasma FFA and TG 
when compared with chow diets. Mice fed the S:n-3 3:1 diet had increased cholesterol levels. 
However, lesion development in these mice was comparable with chow fed mice. The diet 
containing 50% n-3 fats decreased plasma cholesterol levels and reduced atherosclerosis by 40% 
when compared with the chow diet. LDLR-/- mice on high-cholesterol diets with only n-3 FA 
had plasma FFA, TG, and plasma cholesterol levels comparable with low-fat, low-cholesterol 
chow-fed mice. These n-3-fed mice developed much fewer atherosclerotic lesions or moderate 
fatty streaks. 
LpL levels were elevated with increased number of macrophages in the aortic root of 
LDLR-/- mice fed SAT diets. LpL present within the atherosclerotic lesions may anchor more 
LDL for cholesterol deposition. Increased arterial LpL could also lead to increased TG 
hydrolysis to supply extra energy for aortic cells (i.e., metabolically active macrophages in the 





differentiate LpL levels in proximal aorta among LDLR-/- mice that were fed diets containing n-
3 FA in different ratios. Nonetheless, the role of LpL in mediating atherosclerosis is complex. It 
has been shown that overexpression of LpL suppress the diet-induced atherosclerosis in LDLR-/- 
mice (Shimada et al., 1996) and apoE-/- mice (Yagyu et al., 1999). Heterozygous LpL deficiency 
in the vascular wall prevents the retention of atherogenic lipoproteins in LDLR-/- (Semenkovich 
et al., 1998). By contrast, bone marrow transplantation of macrophage overexpressing LpL into 
similar LDLR-/-mice markedly increased atherosclerosis (Babaev et al., 2000). Thus, the tissue-
specific expression of LpL contributes to a discrepancy in the role of LpL in mediating 
atherosclerosis. In our studies, increased LpL in SAT-fed LDLR-/- mice can be associated with 
atherogenesis by mediating uptake and binding of LDL to aortic cells.  However, in LDLR-/- 
mice fed the S:n-3 3:1 or 1:1 diets, with reduced atherosclerosis, the LpL levels were not 
significantly reduced. This suggests that other factors, such as anti-inflammatory factors, may 
counteract effects of LpL in atherogenesis. LpL-facilitated uptake of LDL has been shown to be 
dependent on the LDL receptor (Loeffler et al., 2007). Additional studies are needed for 
clarification.  
 In these studies, we reported that diets containing incremental replacements of SAT by 
n-3 FA block increases in plasma lipid levels and atherosclerosis, and these effects are 
proportional to the amount of n-3 FA in the diets. Replacing dietary saturated fat intake with 
other type of fats is a relevant topic of active interest. In a recent systemic review and meta-
analysis of randomized control trials, strong evidence was found that consumption of PUFA as a 
replacement for SAT lowers CVD risk (Mozaffarian et al., 2010). The pooled risk reduction for 
coronary heart disease events in the intervention groups compared with the controls was 19% 





PUFA diets, the pooled risk for non-fatal myocardial infarction and fatal coronary heart disease 
was significantly reduced by 22% (p=0.005). For n-6-specific PUFA diets, the risk was higher 
than for n-3/n-6 mixtures (Ramsden et al., 2010). Of note, chow diets contain only n-6 PUFA, 
and the other diets utilized in our feeding studies were supplemented with n-6 PUFA to prevent 
essential FA deficiency. Therefore, our findings provide evidence supporting the potentially 
important reduction in CVD risk by modification of dietary fat intake by increasing n-3 FA. 
Several lines of evidence have shown that even low or moderate intakes of n-3 FA 
(250~500 mg/ day) can decrease risk for CVD events (Mozaffarian and Rimm, 2006, Wang et 
al., 2006). In the current studies, we demonstrated that diets with a 25% n-3 replacement of the 
total fat improved plasma lipid profiles and markedly reduced atherosclerosis development. One 
possible mechanism underlying the effects of specific FA on atherosclerosis development may 
be due to regulation of inflammatory responses at the level of the arterial wall. Our data showed 
that SAT increased the arterial macrophage marker, CD68, and classically activated 
inflammatory cytokines, including IL-6 and IL-10, whereas n-3 FA, which made up only 25% of 
total fat, significantly reduced these pro-inflammatory and pro-atherogenic markers. Moreover, 
in our studies, n-3 FA differentially activated “alternatively activated” cytokines, such as IL-12 
(data not shown), that are anti-inflammatory and anti-atherogenic.  
Our current studies were carried out in an atherosclerosis-prone mouse model. In our 
previous studies, we showed that dietary intake of n-3 FA was associated with events to initiate 
atherosclerosis such as elevated cholesterol levels and arterial LDL deposition, even before the 
appearance of the atherosclerotic lesion. Now we demonstrate that n-3 FA are also important in 





CHAPTER 5 : REGULATION OF ARTERIAL LPL   
 
SUMMARY 
Objectives- Dietary FA modulate arterial lipid uptake and deposition, in part, through influencing 
LpL levels in arterial wall. We now examined the cell origins and regulation pathways for LpL 
that could account for increased or decreased levels of arterial LpL.  
Methods and Results- Aortic cell populations that may be linked to LpL levels in response to 
dietary FA were assayed by quantitative IFC. Alexa-labeled LpL was developed to examine 
circulating LpL distribution in the arterial wall. Heparin injection was used to determine extra- 
versus intra- cellular localizations of LpL. Interacting and potential regulatory factors linked to 
LpL levels were examined by RT-PCR or IFC. Dietary FA did not modify circulating LpL 
distribution or degradation. Arterial LpL was differentially associated with different aortic cells 
types; a substantial amount of LpL was macrophage-associated. Approximately 50% of 
macrophage-associated LpL was heparin-releasable and thus probably extracellular. In LpL 
knockout models, deficiency of LpL in the arterial wall reduced aortic macrophage populations 
and macrophage infiltration, while the reconstitution of macrophage expressing LpL led to 
increases in macrophage populations to the arterial wall. Dietary FA modified LpL levels and 
distribution in parallel to changing aortic PPARβ/δ expression; SAT diets increased arterial 
PPARβ/δ expression, whereas n-3 diets decreased it.  Increased Foxo1 expression after feeding 
with n-3 diets might be linked to the decreases in arterial PPARα. Arterial GPIHBP1 was 
associated with macrophages and was also regulated by dietary FA.    
Conclusion- The effects of FA on modulating LpL levels were likely produced locally in the 





macrophages. n-3 FA decrease risk for CVD, in part, by decreasing arterial macrophage-


























LpL in the arterial wall can be produced by monocytes, macrophages and SMC. It is 
postulated that secretion of LpL by each cell type may have different effects on atherosclerosis. 
In the current studies, we characterized the cellular localization of LpL in response to specific 
dietary FA. LpL binds to cell surface PG, such as HSPG on EC (Saxena et al., 1991), and 
heparin releases LpL from cell surface proteoglycans (Iverius et al., 1972). Thus, heparin was 
used to examine LpL localization, intracellular versus extracellular, in the arterial wall. Aortic 
cell populations that are associated with increased or decreased arterial LpL levels in response to 
dietary FA were characterized.  
In the studies described in the earlier chapters, aortic LpL levels were linked to the 
numbers of macrophages. The role of macrophage-derived LpL in lipoprotein metabolism and 
atherosclerosis has been well-defined (Beauchamp et al., 2002); LpL expression by arterial 
macrophages promotes foam cell formation and atherosclerosis (Babaev et al., 1999, Babaev et 
al., 2000). The absence of macrophage-derived LpL reduces atherosclerotic lesion formation 
(Van Eck et al., 2000). Several functions of LpL in mediating atherosclerosis have been 
proposed. When LpL is present in the arterial wall, it can act as a nonenzymatic bridging 
molecule for atherogenic lipoproteins to the extracellular matrix to promote retention; it can also 
cause modification of the lipoproteins to making them more atherogenic (Tabas et al., 2007). The 
importance of LpL for LDL deposition has been demonstrated in recent studies of transgenic 
mice expressing normal human LDL compared with LDL with defects in the PG-binding site of 
LDL-apoB (Gustafsson et al., 2007). The defect in the binding site of LDL decreases the 
retention of LDL and delays the onset of atherosclerosis. Lower levels of normal or defective 





Because the dimeric form of LpL has the ability to link different types of arterial cells, for 
example, monocytes and EC, it is suggested that LpL may function as a monocyte adhesion 
molecule (Mamputu et al., 1997, Obunike et al., 1997, Fisher et al., 2003).  In addition, the 
differentiation of monocytes into macrophages is associated with increased LpL-induced TNF-α 
expression and production (Mamputu and Renier, 1999). Therefore, in a separate set of studies, 
we explored whether LpL directs more inflammatory macrophages to the arterial wall. This 
might lead to a “vicious cycle” of macrophages increasing with increased LpL secretion and 
more macrophages infiltrating into arterial wall. To this end, mouse bone marrow, with or 
without LpL expression, was transplanted into a LpL-deficient mouse model (MCKL0) to study 
the role of LpL in influencing macrophage trafficking. By using the quantitative IFC approach 
that we have developed, we were able to examine the interaction of LpL and macrophages 
directly on the arterial wall. 
To further understand the mechanisms behind the control of LpL by FA, factors that have 
been linked to LpL levels were evaluated. Suggested interacting factors for LpL (i.e., PPAR, and 
newly identified factors) including GPIHBP1 and Foxo1, were characterized in the arterial wall 
as was their potential regulation by dietary FA.   
The results suggest that arterial LpL is differentially associated with different aortic cells 
types. As opposed to SAT diets, n-3 diets markedly reduced LpL and macrophage levels 
(p<0.05), and LpL colocalized with aortic endothelium. SAT increased both LpL and 
macrophages; more than 60% of LpL and macrophages co-localized. Approximately 50% of 
macrophage-associated LpL was heparin-releasable (p<0.05) and likely extracellular. This 
substantial increase of LpL by SAT diets was extracellular and this can contribute to increased 





population and infiltration. The reconstitution of macrophage expressing LpL increased 
macrophage infiltration into the arterial wall.  We hypothesize that n-3 FA decrease risk for 


























Animals and feeding protocols 
C57BL/6 and LDLR-/- mice were fed diets containing specific FA as described 
previously. MCKL0 mice were bred and received bone marrow (BM) transplants from wild type 
C57BL/6 (MCKL0/Wt) or MCKL0 (MCKL0/L0) mice. The breeding and BM transplantation 
were performed by Dr. Itsaso Garcia-Arcos (Dr. Ira Goldberg‟s laboratory). In brief, transgenic 
knockout mice expressing LpL exclusively in muscle (MCKL0) were generated by breeding 
transgenic mice that contained the muscle-specific creatine kinase (MCK) promoter driving a 
human LpL minigene, onto the LpL knockout on C57BL/6 background as described earlier. BM 
transplantation protocol was adapted from the studies described by Han et al (Han et al., 2006). 
Recipient mice were given 100 mg/l neomycin (Sigma-Aldrich) 2 weeks before and after BM 
transplantation. Eight-week-old male mice were lethally irradiated with 13 Gy from cesium in 
two doses separated by 4 h. BM was collected from femurs and tibias of donor mice by flushing 
with sterile medium (RPMI 1640, 2% FBS, 5 u/ml heparin, 50 u/ml penicillin, 50 μg/ml 
streptomycin). Each recipient mouse was injected with about 3–5 × 106 bone marrow cells. Four 
weeks after BM transplantation, peripheral blood was collected from the tail vein for PCR to 
check donor bone marrow reconstitution. Once reconstitution was confirmed, recipient mice 
were placed on a high-fat diet for 8 weeks (Research diet D12492). Aortas were collected for 
analyses at the end of the feeding. 
 
LpL labeling 
Bovine LpL was prepared as described previously (Bengtsson-Olivecrona and 





(Molecular Probes). LpL (0.5 mg/ml) in 0.2 M NaHCO3, 1 M NaCl, pH 8.4, was incubated with 
Alexa Fluor 633 at 4°C in the dark for 1 h. The reaction was stopped by the addition of lysine to 
a final concentration of 1 mM. The mixture was diluted with 20 mM bis-tris, pH6.5, and 
immediately applied on a column of heparin-Sepharose. Labeled LpL was eluted by a linear 
gradient of NaCl in the bis-Tris buffer. LpL activity in each fraction was assayed by measuring 
the hydrolysis of a [
3
H] labeled Intralipid with apoCII. The radioactivity of FFA released by LpL 
from each fraction was shown on the y-axis. The specificity of 1-m-unit of LpL activity is ~360 
DPM=1 nmole FFA. Most of the active labeled LpL was eluted with a peak at 1 M NaCl. 
Fluorescent intensity of labeled LpL was measured from each collected fraction by a 
spectrophotometer. These studies were performed in collaboration with Dr. Gunilla Olivecrona 
at Umea University (Sweden). 
The incorporation of Alexa into LpL (dye to protein ratio) was characterized by the 
degree of labeling (DOL), DOL=Amax/[LpL] x εdye, where Amax is absorbance of Alexa-LpL at 
their maximum wavelength, εdye is the extinction coefficient of Alexa 633, and [LpL] is the 
concentration of the labeled LpL. εdye is 100,000 for Alexa Fluor 633 provided by Molecular 
Probes. The concentration of LpL was calculated from absorbance, A280(1%)=1.68 (Lookene et 
al., 2004, Olivecrona et al., 1982).  
To characterize fluorescent-labeled (FL-labeled) LpL in vivo, mice were injected with 
FL-labeled LpL or non-labeled bovine LpL (40 μg LpL/ mouse). Injected LpL was assayed by 
IFC 10 min after injections in the organs. In a separate set of studies, C57BL/6 mice were fed a 
chow, SAT, or n-3 diet for 12 weeks. Fluorescent-labeled LpL was injected into mice 10 min 
before sacrifice. Labeled LpL was determined using a laser scanning confocal microscope as 






Heparin-mediated cell-dissociation of LpL 
C57BL/6 mice were injected with heparin (100 IU/kg body weight) 10 minutes before 
sacrifice at the end of the feedings. Aortas were collected as described in the previous chapters. 
Excised arteries were assayed for LpL activity and localization as previously described. 
 
Colocalization studies 
The colocalization of arterial LpL with aortic cells was examined by IFC similar to the 
process as described in Chapter 2 through 4.
 
The patterns of Alexa 488, 546 and 647 three 
channel colocalization were analyzed by a threshold-based overlap analysis, which is a binary 
test of whether the 3 signals occur in the same or in different regions using ImageJ 1.41 with the 
Colocalisation plug-ins (Lachmanovich et al., 2003). The percentage of colocalization of aortic 
macrophages, SMC, or EC with LpL was quantitated as the percentage of macrophages, SMC, or 
EC containing pixels that also contained LpL signals. Quantitative analyses were performed by 
at least two individuals with the data labels in blinded fashion.  
 
Laser capture microdissection (LCM) 
Aorta sections of LDLR-/- mice were prepared as described in Chapter 4. Aortic 
macrophages were extracted by LCM. Macrophages were detected on slides using an adapted 
rapid staining protocol (Trogan et al., 2002). Sequential slides with corresponding area of 
macrophages were stained with Harris modified hematoxylin (Fisher Scientific) and were 
subjected for microdissection. Laser capture was performed using PALM MicroBeam IV 





laser that can be precisely guided for microdissection. PALM Robosoftware was used for the 
control of microdissection, laser function and contact-free transport. In brief, the UV laser 
microbeam was coupled to the objective of the microscope. A motorized controlled microscope 
stage was attached to the inverted microscope and camera to enable the observation of the 
microscopic image on a computer screen. Macrophages were identified in stained sections under 
transmitted light at x20 magnification. Slides stained for macrophages were used to navigate and 
select macrophage-containing areas on the adjacent slides. Microdissection was performed by 
cutting around the perimeters of the selected area with a fine focused laser beam. After cells 
were isolated, pulses of the focused laser beam just below the focal plane of the tissue specimen 
were used to create a pressure wave separating the targeted tissue from the slide and catapulting 
it against gravity into the microcentrifuge cap containing 50 μl RNA lysis buffer. Immediately 
after the microdissection, a further 170 μl of RNA lysis buffer was added to the tube, followed 
by centrifugation to spin down cells from the lid. The samples were stored in -80°C before RNA 
extraction. RNA extraction and analyses from collected aortic macrophages were performed 
following the manufacturer‟s instructions (MicroRNA Isoaltion kit, Stratagene).  The extracted 
RNA was amplified with a MessageAmp II aRNA Amplification Kit (Ambion).   
 
Quantitative real-time RT-PCR  
Total RNA was isolated from a proximal portion of the aorta with TRIzol reagent 
(Invitrogen). Single strand cDNA was synthesized from RNA using iScript reverse transcriptase 
according to the manufacturer‟s instructions (Bio-Rad). Quantitative real-time PCR was carried 
out on an iCycler (Bio-Rad) using the SYBR Green PCR kit (Applied Biosystems). Results were 





genes (ΔCt). Changes in the threshold crossing (ΔCt) were used to calculate relative levels of 
each mRNA using the formula 2
–ΔCt
. All real-time PCR reactions were carried out at least twice 
from independent cDNA preparations. Table 5-1 lists the primer sequences. 
 
Statistical analyses 
Student‟s t-tests of group means were used to compare endpoints and ANOVA was used 
to evaluate potential interactions between diets. Statistical significance was determined at the 









Primer Forward Primer  Reverse Primer 
PPARα CCTCTTCCCAAAGCTTGACAAGT ATTAAGTTACAACAGTCAGTCCAAGCA 
PPARγ ATCTACACGATGCTGGC GGATGTCCTCGATGGGG 
PPARβ/δ AGATGGTGGCAGAGCTATGACC TCTCCTCCTGTGGCTGTTCC 
LpL AACCACGGCCTTCCCTACTTC GCCATTGCACAACTCTTTTCTCAT 
Foxo1 CAAAGTACACATACGGCCAATCC CGTAACTTGATTTGCTGTCCTGAA 
GPIHBP1 AGCAGGGACAGAGCACCTCT AGACGAGCGTGATGCAGAAG 
GAPDH TGCAGTGGCAAAGTGGAGAT TTGAATTTGCCGTGAGTGGA 
 







Characterization of fluorescent-labeled LpL  
To develop a new tool to study the localization of LpL, bovine LpL was labeled with 
fluorescent Alexa 633 succinimidyl ester to form a carboxamide bond on LpL lysine residues. 
Labeled LpL was purified by the affinity chromatography using a heparin-Sepharose column. 
LpL was eluted onto the column and measured for its activity (Figure 5-1). Similar to that of 
unlabeled LpL, most labeled LpL eluted at the high salt concentration, ~1 M NaCl, and remained 
catalytically active (Figure 5-1). 
Labeled LpL collected from the columns was further characterized by a 
spectrophotometer at different wavelengths to measure the absorbance of LpL protein levels 
(primary y-axis) and fluorescent intensity of Alexa Fluor 633 (secondary y-axis) (Figure 5-2). 
The overlapping peaks indicated that LpL protein levels corresponded to fluorescent intensities 
of labels. Note that the peaks close to fraction 16
th
 also contained the most active LpL as shown 
in Figure 5-1. The dye to protein ratio (DOL) was 1.5. Taken together, these results showed the 
labeling of LpL with Alexa 633 which did not change the functional properties of LpL.  
To examine the circulation and tissue distribution of labeled LpL, either Alexa-labeled 
LpL from fraction 16 or non-labeled bovine LpL were injected into C57BL/6 mice. Tissue 
distribution of fluorescent-labeled LpL was similar to the exogenously added bovine LpL, as 
reported in the study by Neuger (Neuger et al., 2004), in which most of the injected LpL was 
taken up rapidly by liver (Figure 5-3A). Very little or no LpL was found in the artery.  
Using labeled LpL as a marker for exogenous/circulating LpL, we then went on to 
determine whether diet could modify LpL metabolism and LpL tissue distribution. C57BL/6 





n-3 diets. At the end of the feeding periods, mice were injected with fluorescent-labeled LpL 10 
min before sacrifice. Liver took up most of the injected LpL regardless of the diet; very little 
injected LpL was found in LpL-producing tissues, including heart, muscle, and adipose tissue. 
Exogenously injected LpL was not found in the aorta (Figure 5-3B). Thus, we suggest that 
dietary FA have no direct effects on circulating LpL distribution or degradation. It is likely that 
the effects of diets on modulating levels of LpL as described in the previous chapters were 

































Figure 5-1: Alexa-labeled LpL activity. 
Labeled LpL was purified by the affinity chromatography using heparin-Sepharose column 
as described in Methods. LpL activity in each fraction was assayed by measuring the 
hydrolysis of a [
3
H] labeled Intralipid with apoCII. The radioactivity of free fatty acids 























































Figure 5-2: LpL levels correspond to Alexa 633 fluorescent intensity. 
Fractions collected from the column were measured for the absorbance of LpL protein (■) and dye-
Alexa 633 (▲), fluorescent intensity, at wavelength of 280 nm or 633 nm, respectively. The primary y-
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Figure 5-3: In vivo characterization of Alexa-labeled LpL. 
(A) Alexa-labeled LpL was injected into mice 10 min before sacrifice. Confocal fluorescence of 
endogenous, exogenous non- or Alexa-labeled LpL was determined in liver for comparison. (B) At 
end of 12-weeks of being fed chow, SAT or n-3 diets, mice were injected with Alexa-labeled LpL 10 
min before sacrifice. Labeled LpL was determined in specific tissues with a nucleus marker (Sytox 







Effects of diet on aortic LpL and aortic cell populations 
We have previously reported that increases in arterial LpL were linked to increased 
numbers of local macrophages. To determine the interaction of arterial LpL and specific aortic 
cells in response to specific dietary FA, C57BL/6 mice were fed a chow, SAT, or n-3 diet for 12 
weeks. Aorta sections have been stained with specific fluorescent markers for LpL and aortic 
SMCSMC, macrophages (MΦ), and EC by IFC. SAT-fed mice had increased green fluorescence 
of LpL and red fluorescence of macrophages in aortas when compared with chow-fed mice; most 
aortic LpL was colocalized with macrophages as indicated by yellow fluorescence in the merge 
image. There were few macrophages and little LpL detected in n-3-fed mice, where LpL 
colocalized with macrophages at the endothelium (Figure 5-4).  
Quantification of LpL and aortic cell markers showed that SAT diets led to significant 
increases of more than 50% in aortic macrophages and LpL levels when compared with the chow 
diet (p<0.05). By contrast, n-3 decreased aortic LpL and macrophages (Figure 5-5). Numbers of 
EC and SMC were not changed. Correlation of LpL localization and aortic cells was examined 
by the colocalization of aortic cells, EC, macrophages, or SMC with LpL. The results showed 
that SAT diets markedly changed aortic cell associations with LpL; macrophage-associated or 
EC-associated LpL was increased compared with chow or n-3 diets. n-3-fed mice had the least 
LpL colocalized with all cellular markers (Figure 5-6). Notable amounts of LpL were found in 
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Figure 5-4: Effects of diet on aortic LpL and cells. 
Representative images of chow-, SAT-, or n-3-fed mouse arteries stained for endothelial cells (EC), LpL 




































Figure 5-6: Colocalization of aortic cells with LpL in response to dietary FA. 
Percentage of EC, SMC, and MΦ colocalizing with LpL was determined in each group (n>4), 



























Figure 5-5: Quantitation of aortic LpL and cells in response to dietary FA. 
Confocal fluorescence of arterial EC, SMC, LpL and MΦ quantitated in C57BL/6 mice after 
feeding with chow, SAT or n-3 diets. Each group consisted of at least four mice; >15 











Heparin-mediated cell dissociation of LpL 
To further characterize the mechanisms behind arterial LpL localization and levels in 
response to dietary FA, we used heparin, which releases LpL from cellular surfaces, to examine 
the intra- or extra-cellular localization of LpL. C57BL/6 mice were fed a chow or a high fat diet 
enriched in SAT or n-3 for 12 weeks. At the end of the feeding periods, mice were or were not 
intravenous injected with heparin 10 min before sacrifice.   
Because intravenous administration of heparin is known to increase LpL concentration in 
circulation, plasma lipid profiles of these mice were examined to validate the release of LpL into 
plasma by heparin. In the non-heparin-injected feeding groups, consistent with our previous 
findings, n-3 diets decreased plasma FFA, TG and cholesterol when compared with chow diets 
(Figure 5-7). Mice fed SAT diets had elevation of all plasma lipids. The injection of heparin 
accelerated the release of plasma FFA, and these increases corresponded to decreases in plasma 
TG levels in all feeding groups (Figure 5-7A and 5-7B). Plasma cholesterol levels were not 
affected by the heparin injection (Figure 5-7C). Therefore, heparin-releasable LpL increased TG 
hydrolysis in blood.  
To investigate heparin-mediated LpL dissociation from the arterial wall, we determined 
aortic LpL activity in these mice after diets. The results showed that the diets did not alter aortic 
LpL activity, as indicated in Figure 5-8 (open bars). Injection of heparin disassociated LpL from 
aortic cell surfaces, LpL catalytic activity decreased or tended to be reduced in each feeding 
group (filled bars). Significant reduction of LpL activity was found in n-3-fed mice in which a 























































Figure 5-7: Effects of diet and heparin on plasma lipid profiles. 
Blood samples were determined for FFA (A), TG (B), and Chol (C) levels as described in 
Methods. The results are expressed as the mean±SE (n=10). 
#
, (-) vs. (+) heparin; *, SAT/n-3(-) vs. 
chow (-) ; **,SAT (-) vs. n-3(-) ; 
†
,SAT/n-3(+) vs. Chow(+) ; 
‡
























Using the methodologies developed in our laboratory for quantification of cell markers 
and colocalization, we were able to examine the changes of LpL and specific aortic cells after the 
injection of heparin. Aortic LpL was released after heparin (Figure 5-9A). Significant reductions 
of post-heparin arterial LpL were found in SAT- and n-3-fed mice (p<0.05, Figure 5-9B). The 
percentage of total arterial heparin-releasable LpL was affected by diet (Figure 5-10A). However, 
heparin has major effects on releasing macrophage-associated LpL (Figure 5-10B), especially in 
SAT fed mice, indicating the significant amount of macrophage-associated LpL is extracellular 
and able to “anchor” LDL delivery and deposition. It is of interest that macrophage number also 
decreased after the injection of heparin, especially in SAT fed mice (Figure 5-9B). We 
hypothesized that macrophages adhere to arterial cells, in part, through LpL. Thus, heparin 



























Figure 5-8: Effects of heparin and diet on arterial LpL activity. 
At end of feedings with chow, SAT, or n-3 diets, C57BL/6 were (filled bars) or were not (open 
bars) injected with heparin 10 min before sacrifice. Mouse artery homogenates were determined 












































































Figure 5-9: Effects of heparin on aortic LpL and cells. 
(A) Images shown are colocalization of aortic EC (blue), LpL (green), and macrophages (red) in 
C57BL/6 mice fed chow, SAT or n-3 diets pre- or post-heparin injection.  Magnification is 40x. (B) 
Confocal fluorescence of cell markers quantitated in each group. #, (-) vs. (+) heparin; *, SAT/n-3(-) 












The role of LpL in regulating arterial macrophage levels 
To investigate the role of LpL in influencing macrophage trafficking in the artery in vivo, 
mice that lacked LpL expression in the arterial cells (MCKL0) were transplanted with bone 






































Figure 5-10: Quantification of aortic LpL and cells in response to heparin and dietary 
FA. 
(A). Percentage of LpL released after heparin was determined for each group. (B). Percentage of 
macrophage-specific LpL released after heparin was determined for each group. *, SAT/n-3 vs. chow; 








transplantation, mice were placed on high saturated-fat diets for 8 weeks. Arterial macrophages 
were assayed at the end of the feeding periods (Figure 5-11). Arterial LpL mRNA transcription 
(Figure 5-12A) was significantly reduced in MCKL0/L0 mice (p<0.05), validating the deletion 
of LpL in the arterial cells. The deletion of LpL in the arterial wall was associated with a >20% 
reduction in arterial macrophage populations when compared with wild-type C57BL/6 mice 
transplanted with wild-type mouse bone marrow (Wt/Wt). Some LpL was found in the arterial 
wall of MCKL0/L0 mice, and reduced arterial macrophages were associated with decreases in 
arterial LpL in MCL0/L0 mice. On the other hand, the reconstitution of wild type bone marrow 
into MCKL0 mice significantly increased aortic macrophages (p<0.05), and the distribution 
pattern of  LpL and macrophage was comparable with that of wild-type mice (Figure 5-12B).  
Quantification of macrophages in different aortic layers showed that the deletion of LpL 
led to reduced macrophage number and macrophage infiltration; aortic medial macrophages were 
significantly reduced (p<0.05, Figure 5-12C).  
To examine the potential mechanisms underlying the control of macrophage population 
in arterial wall, we examined pro-inflammatory adhesion molecule levels (Figure 5-13). 
Chemoattractant – MCP-1 tended to be reduced in artery homogenates of MCKL0/L0 mice when 
compared with MCKL0/Wt (Figure 5-13A). This is probably associated with the reduced 
number of macrophages. However, the vascular adhesion molecule, VCAM-1 (Figure 5-13B), 
was increased in MCKL0/L0 mice. The underlying mechanisms are not clear.        
 
 







                                                                                                                                                                    MCKL0/L0 MCKL0/Wt 
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Figure 5-11: Effects of arterial LpL deletion on macrophage distribution. 
Images shown are artery sections stained for EC (green) and MΦ (red) in MCKL0/L0 (-LpL) and 
























































Figure 5-12: LpL mRNA expression and localization in proximal aorta in MCKL0/L0 
and MCKL0/Wt mice on high fat diets.  
(A) LpL mRNA expression determined for each group. (B) Representative images of MCKL0/L0 and 
MCKL0/Wt mouse artery sections stained for EC. LpL, and MΦ. (B) Confocal fluorescence of MΦ in 















Factors that are linked to LpL levels in response to dietary FA 
Many factors have been suggested to influence and interact with LpL expression. 
Suggested interacting factors include ligand-activated transcription factors – PPAR family. 
Binding of PPAR to the peroxisome proliferator response element (PPRE) consensus sequence 
















































Figure 5-13: Arterial MCP-1 and VCAM-1 mRNA expression in proximal aorta of 
MCKL0/Wt vs. MCKL0/L0 mice.  
Artery homogenates were determined for mRNA of MCP-1(A), and VCAM-1(B) expression as 







β/δ, and γ, differ in their tissue distribution and ligand specificity. FA and their derivatives (i.e., 
eicosanoids) are endogenous ligands for PPAR. In the current studies, arterial PPAR expression 
was examined in mice that were fed chow, SAT, or n-3 diets. SAT diets markedly increased 
PPARα mRNA but slightly decreased PPARγ levels in mice compared with chow diets. n-3 diets 
significantly increased both PPARα and PPARγ levels. By contrast, PPARβ/δ levels were only 
increased by SAT but were decreased by n-3, suggesting a role in influencing LpL levels (Figure 
5-14).   
A relatively “new” identified factor potentially relating to LpL, Foxo1, was examined. 
The results showed a greater than two-fold increase of Foxo1 expression in mice fed n-3 diets 
(p<0.05, Figure 5-15). SAT fed mice had Foxo1 mRNA levels similar to those of chow-fed mice.  
Although expression of GPIHBP1, a lipase anchoring protein at the endothelium, has not 
been described in arteries, it is intriguing that immunoreactivity of GPIHBP1 in arteries was 
detected in our studies (Figure 5-16A). We have also observed that SAT diets appeared to 
increase and n-3 diets seemed to decrease GPIHBP1 in the arteries when compared with chow 
diets. GPIHBP1 mRNA levels seemed to increase in mice on n-3 diets (Figure 5-16B).  
Contrary to data on immunofluorescent LpL in the arterial wall, LpL mRNA levels were 
not modified in mice after diets. Because of the artery homogenates were used for measuring 
LpL mRNA expression, we postulated that cellular heterogeneity can interfere with the 
measurement of expression of specific genes.  We hypothesized that macrophage secretion of 
LpL is responsible for increased LpL levels. To test these hypotheses, aortic macrophages in 
LDLR-/- mice were extracted by LCM for gene analyses. The results showed that LpL levels 
were indeed significantly increased in aortic macrophages from SAT-fed mice, while n-3 





were also different from whole artery homogenates. PPARβ/δ mRNA levels were similar in 
whole artery homogenates and in macrophages, suggesting that macrophages, not other arterial 
cells, control arterial levels of PPARβ/δ (Figure 5-18). 
Collectively, we have showed that dietary FA had direct effects on LpL modulating 
factors that could play an important role in arterial wall LpL levels and distribution, and as well 






























































































Figure 5-14: Effects of diet on arterial PPAR mRNA expression. 
C57BL/6 mice were fed a chow, SAT or n-3 diet for 12 weeks. Arterial mRNA of PPARα (A), 
PPARγ (B), and PPARβ/δ (C) was determined in each group as described in Methods. *, SAT/n-














































Figure 5-15: Effects of diet on arterial Foxo1 mRNA in proximal aorta in C57BL/6 
mice. 










































Figure 5-16: Effects of diet on aortic GPIHBP1 transcription and 
immunofluorescence in C57BL/6 mice.   
Mice were fed chow, SAT or n-3 diets for 12 weeks. (A) Artery sections were stained for 
GPIHBP1, LpL or macrophages in each group. (B) Artery homogenates were determined for 
GPIHBP1 mRNA levels in each group. Data are expressed as the mean±SE. *, SAT/n-3 vs. chow; 









































Figure 5-17: Effects of diet on macrophage-specific LpL mRNA expression. 
LDLR-/- mice were fed chow, SAT or n-3 diets for 12 weeks. Aortic macrophages were collected by 























































































Figure 5-18: Effects of diet on macrophage-specific PPAR mRNA expression. 
LDLR-/- mice were fed chow, SAT or n-3 diets for 12 weeks. Aortic macrophages were collected 
by LCM for measuring PPARα (A), PPARγ (B), and PPARβ/δ (C) mRNA in each group as 










These studies have provided insights into the control and cells of origin of arterial LpL in 
response to dietary FA. The colocalization studies showed that arterial macrophages were the 
major source for increased arterial LpL, particularly in the aortic media. By contrast, diets rich in 
n-3 FA decreased the levels of aortic medial LpL; LpL was associated with macrophages in the 
intimal area. Furthermore, LpL was released from cell surfaces after heparin injection, showing 
that a significant amount of macrophage-associated LpL was extracellular where it likely can 
“anchor” LDL for uptake and deposition. It is of interest that a notable amount of LpL was found 
in the aortic adventitial layer, especially in mice fed n-3 diets. Our preliminary data on 
quantitating arterial macrophages in specific aortic layers, i.e., intima vs. media vs. adventitia, 
showed a significant amount of macrophages were in the aortic adventitial layers. Therefore, 
LpL counted in the n-3 fed group might be derived from macrophages in aortic adventitia, which 
could account for potential dilution effects in quantification. Additional studies are needed to 
investigate the role of LpL at the adventitia. 
Surprisingly, arterial macrophages were also released after heparin injection. The 
phenomenon of “heparin-releasable macrophages” is not well-known. Thus, we explored the 
interaction of aortic LpL and macrophage levels. The results showed that LpL can act as 
macrophage adhesion molecule; when LpL was depleted in the artery of MCKL0/L0 mice, the 
number of macrophages decreased. On the other hand, the reconstitution of LpL expression in 
macrophages increased aortic macrophage populations. This suggests that the heparin that 
releases cell surface LpL, can also release LpL-bound macrophage from the artery. 
In the current studies, we used Alexa-labeled LpL as an exogenous LpL marker. 





macrophages (Hendriks et al., 1996). It should be noted that, when exogenously added LpL was 
mixed with lipoproteins and added to the cells, LpL formed a complex with the lipoproteins 
before acting as a bridge. Therefore, LpL in this complex might function in a different way from 
LpL produced by aortic cells. On the other hand, Wang et al. (Wang et al., 1999) have reported 
that macrophages were able to produce LpL in amounts sufficient to enhance the binding and 
uptake of native, mildly oxidized or moderately oxidaized LDL. Taken together, although we 
have not studied the binding and uptake of LDL after the injection of labeled-LpL, our in vivo 
characterization of labeled-LpL showed the absence of exogenously injected labeled-LpL in 
arterial wall. This suggests a minor role, if any, for circulating LpL in mediating LDL deposition 
in the arterial wall. One potential limitation of our studies using injected labeled-LpL is that after 
labeling and intial characterization, labeled LpL may have changed some properties during 
storage. 
 A A large body of evidence suggests a role for PPARs in mediating multiple biological 
events (Rader and Pure, 2005). It has been shown that macrophage-specific deletion of PPARγ 
resulted in increased atherosclerosis in mice (Chawla et al., 2001), whereas genetic deletion of 
PPARα (Tordjman et al., 2001) and macrophage-PPARβ/δ (Lee et al., 2003a) resulted in reduced 
atherosclerosis. Our findings showed diverse expression among all three arterial PPAR in 
response to dietary FA. PPARα and PPARγ expression levels were differentially regulated by 
dietary FA in proximal artery homogenates versus extracted macrophages. PPARβ/δ were 
increased by SAT diets but decreased by n-3 diets in both systems. The interaction of LpL and 
PPAR has been examined elsewhere. For example, treatment with natural FA-derived PPAR 
activators, such as PA, stearic and linoleic acids increased both extra- and intra-cellular LpL 





data on treatment of macrophages with synthetic ligands to PPAR are controversial. Both 
PPARα and PPARγ agonists inhibited foam cell formation, whereas a PPARβ/δ agonist in vivo 
did not (Li et al., 2004). Treatment of macrophages with a PPARα agonist has been shown to 
inhibit inflammatory gene expression in vitro (Lee et al., 2003a, Welch et al., 2003). The role of 
PPARβ/δ in macrophage inflammatory responses is different, in that in the absence of ligand, 
PPARβ/δ promotes macrophage-inflammation (Lee et al., 2003a, Plutzky, 2003). These can all 
contribute to changes in arterial LpL levels and activity. Mechanisms behind the differential 
regulation of PPAR levels on LpL include the specificity of natural versus synthetic compounds 
and the transcription factors that recognize the putative PPAR sequence present in the LpL gene. 
Moreover, FA can stimulate PKC that regulates LpL gene at the post-transcriptional levels 
(Beauchamp et al., 2004). The role of PPARs in regulation of arterial wall LpL needs more 
definition. 
It is of interest that LpL-mediated extracellular lipolysis can influence PPAR activation. 
Exposure of EC to LpL-treated VLDL differentially activated all three PPAR 
(PPARα>>PPARβ/δ>PPARγ), resulting in inhibition of inflammatory responses in a PPAR-
dependent manner (Ziouzenkova et al., 2003). Exposure of macrophages to VLDL resulted in the 
activation of PPARβ/δ, and to a lesser extent, PPARα (but not PPARγ). This effect was 
substantially enhanced by co-incubation with LpL (Chawla et al., 2003).  
Moreover, the PPAR family of nuclear receptors and the Foxo (forkhead box class O) 
family of winged helix/forkhead box factors are key families of transcription factors for the 
regulation of FA and glucose metabolism. The interaction of nuclear receptors and the forkhead 
family (e.g. PPARγ and Foxo1) has been demonstrated (van der Vos and Coffer, 2008). It has 





mechanism by which Foxo1 inhibits PPARγ function is through disrupting formation of a 
PPARγ/RXR complex, which results in loss of DNA binding (Dowell et al., 2003), leads to  the 
up- or down-regulation of down-stream PPARγ target gene expression (Armoni et al., 2006), 
including LpL. Foxo1 can also function as a coactivator of PPARα. Foxo1 was found to enhance 
expression of LpL in a myocyte cell line. Foxo1 induced LpL levels increased even further in the 
presence of PPARα ligands (Kamei et al., 2003). However, it is not clear whether this was due to 
a direct interaction between PPARα and Foxo1. Conversely, it has been shown that PPARα 
inhibits Foxo1 transcriptional activity by decreasing the DNA binding capacity (Qu et al., 2007). 
In our current studies, n-3 diets decreased LpL and PPARα expression levels. We hypothesized 
that the decrease in LpL levels from n-3 diets may be linked to the increased Foxo1 levels. More 
studies are needed to provide more definitive answers.  
In summary, the control and cell origins of LpL in response to dietary FA have been 
investigated. Arterial LpL was differentially associated with specific aortic cell types. Interacting 
factors, such as PPARβ/δ, likely play an important role in regulation of arterial-wall LpL levels 
in response to FA. The presence of GPIHBP1 in the arterial wall indicates that other pathways 
must be involved in mediating changes of LpL levels and arterial lipid deposition. Increased LpL 
in SAT-fed mice was correlated with aortic macrophages. Our findings indicate that LpL can 










CHAPTER 6 : CONCLUSIONS AND FUTURE DIRECTIONS 
 
 The studies described herein have provided new insights into the mechanisms through 
which dietary FA, metabolic syndrome and LpL interact to influence arterial lipid uptake and 
other factors linked to atherogenesis. We investigated underlying pathways of regulation of 
arterial LpL and how LpL modulates arterial lipid deposition in the development of 
atherosclerosis. We have reported that saturated fat-enriched diets increase arterial LDL uptake 
and SU, and this was associated with increased arterial LpL (Seo et al., 2005). In contrast with 
the well-documented adverse effects of SAT on atherosclerotic CVD, consumption of PUFA, 
particularly those rich in very long-chain n-3 FA, such as EPA and DHA, potentially reduce the 
risk for CVD. Therefore, we hypothesized that specific FA, SAT versus n-3, alter the recruitment 
of different cell populations to the arterial wall, modulate arterial LpL levels and distribution, 
and thus affect the development of atherosclerosis. To test these hypotheses, we carried out a 
series of dietary feeding studies in different mouse models to demonstrate the effects of saturated 
versus n-3 FA on LDL-cholesterol delivery to the arterial wall and arterial LpL levels.  
In Chapter 2, we reported that diets rich in n-3 FA markedly reduced arterial LDL whole 
particle and selective LDL cholesterol uptake relative to diets rich in saturated FA; these effects 
of FA on arterial LDL uptake were independent of plasma cholesterol levels.  We have further 
demonstrated that changes in arterial LDL delivery and deposition were related to changes in 
LpL expression and distribution in the arterial wall. Using the method that we developed to 
quantify IFC of LpL, we demonstrated that arterial medial LpL levels were increased by 
saturated FA-enriched diets. By contrast, n-3-FA-enriched diets diminished the levels of medial 





delivery to the arterial wall can be modified by diet, in part, through reducing arterial LpL levels 
in the very early stages of atherosclerosis.  
Type 2 diabetes has emerged as a major CVD risk factor. Insulin resistance is a major 
pathophysiological event underlying the current epidemic of CVD and type 2 diabetes. 
Therefore, we explored whether n-3 FA influence arterial cholesterol delivery and LpL in a state 
of insulin resistance. In Chapter 3, the results of feeding studies in L1 mice showed that L1 mice 
were prone to accumulation of arterial LDL cholesterol, and this was linked to elevated arterial 
LpL levels. As opposed to SAT diets, n-3 diets markedly reduced all plasma lipids. Although 
both SAT- and n-3-fed groups had elevated plasma insulin levels, the n-3-fed mice had blood 
glucose levels similar to the chow-fed mice. Under the circumstances in which L1 mice have 
relatively normal β-cell function, it is likely that SAT-fed mice with persistent severe 
hyperinsulinemia and hyperglycemia can proceed to β-cell dysfunction in terms of insulin 
secretion.  These findings suggest that qualitative differences in dietary FA are more important in 
influencing blood glucose, in addition to their effects on plasma lipid levels.   
We then examined the effects of these dietary FA on arterial LDL uptake in the L1 
model. SAT diets markedly increased LDL and LDL-cholesterol uptakes and this was associated 
with increased arterial LpL levels in L1 mice. n-3 FA ameliorated abnormal plasma lipid profiles 
in L1 mice. Consistent with the findings reported in Chapter 2, n-3 diets reduced arterial LpL 
levels, total LDL, and selective LDL-cholesterol uptakes in L1 mice. 
In addition to the method of quantification of immnunofluorescence in a single color 
channel, we have also developed new methods to quantify the colocalization of multiple 
fluorescent signals. Based on this method, we examined the correlation between arterial LpL 





showed that the presence of LpL was linked to arterial medial macrophages. SAT diets increased 
levels and colocalization of LpL and macrophages in arterial wall. In n-3 fed mice, little LpL and 
few macrophages were found in aortic media.   
These studies described above were carried out in mice (i.e., C57BL/6 and L1 mice) with 
no identifiable atherosclerotic lesions, or fatty streaks. To further explore the effects of dietary 
FA on the extent and severity of atherosclerotic lesion development, LDLR deficient mice were 
chosen as an atherosclerosis model in Chapter 4. We demonstrated that feeding LDLR-/- mice 
with diets containing incremental replacements of SAT with n-3 fats was inversely correlated 
with the increased plasma lipids and atherosclerosis. Similar to the findings in humans, the 
results showed that diets in which n-3 FA comprise as little as 25% of the total fat content 
improved abnormal lipid profiles and reduced atherosclerosis in LDL-receptor null mice, and 
these effects are independent of dietary cholesterol intake. 
However, the cell origins of arterial LpL in mediating LDL uptake and CE deposition 
were still unclear. In Chapter 5, characterization of Alexa-labeled LpL in vivo revealed that 
increased arterial LpL was not associated with injected labeled LpL in the arterial wall. We 
suggest that increased LpL in response to SAT was locally produced by arterial cells–
macrophages and, possibly SMC. Questions arose whether the injection of labeled LpL can 
influence the uptake of LDL. Injected LpL in the circulation could interact with LDL before LpL 
interacted with arterial cells or other tissues. Injected LpL in this complex might have different 
function from LpL produced by macrophages locally in the arterial wall. Therefore, further 
studies of binding and uptake of LDL with injected LpL will differentiate the role of LDL-bound 
LpL from cell surface-bound LpL in mediating arterial LDL uptake and deposition. The in vivo 





evidence on the interaction of arterial LDL and LpL. Also, it is possible that Alexa-labeled LpL 
was initially active but may have converted to be inactive for liver uptake. Thus, stainning of 
specific cells in liver, such as hepatocytes, Kuppfer and endothelial cells, with injected Alexa-
labeled LpL will provide a more definitive answer. 
Also, in Chapter 5, the data on the injection of heparin into mice demonstrated the 
cellular localization of LpL; a significant amount of macrophage-associated LpL was 
extracellular as indicated by being heparin-releasable. This may account for its increased 
“anchoring” activity. The unexpected result was the reduction of macrophages after heparin. This 
led to studies described in Chapter 5, where our data showed that loss of LpL is associated with a 
reduction in arterial macrophages, suggesting that LpL can act as a bridging molecule not only 
for LDL but also for macrophages and/or monocytes. Our preliminary data has confirmed that 
the deletion of LpL in the arterial wall led to decreased macrophage transcription. Additional 
studies are needed to confirm these changes, including the investigation of the effects of n-3 FA 
on these artery-specific LpL deficient mice. We hypothesize that dietary intake of n-3 FA, in 
addition to decreasing pro-atherogenic LpL, will result in a greater reduction of arterial 
macrophages and macrophage infiltration that are linked to atherosclerosis development. 
The examination on the mRNA levels of LpL, Foxo1, and PPAR provided the evidence 
that PPAR and Foxo levels were modulated by specific FA and that these changes can relate to 
LpL expression. It has been shown that PPAR modulates LpL expression through its binding 
activity to target LpL promoter. In the studies described in Chapter 5, PPAR  and PPAR  levels 
were both slightly increased in mouse artery homogenates in n-3-fed mice relative to chow-fed 





decreased by n-3. LCM data of aortic macrophage-specific expression of these molecular 
markers further indicated that the changes of PPARβ/δ expression levels were consistent in 
proximal artery homogenates and macrophages in response to dietary FA. Feeding PPARβ/δ 
knockout mice with SAT or n-3 FA diets will confirm the role PPARβ/δ in mediating arterial 
LpL expression. 
GPIHBP1 was found in the arterial wall. SAT increased GPIHBP1 levels and increased 
colocalization of GPIHBP1 and macrophages. However, the transcription of GPIHBP1 was 
increased in n-3-fed mice. Although the presence of GPIHBP1 in aorta has not been shown 
elsewhere, chow-fed GPIHBP1 knockout (GPIHBP1-/-) mice developed spontaneous 
atherosclerotic lesions (Weinstein et al., 2010); however, the lesions in GPIHBP1-/- mice are 
small and require more time to develop than those of apoE-/- or LDLR-/- mice. GPIHBP1-/- 
mice have chylomicronemia; it is possible that these TG-rich lipoproteins cause atherosclerosis 
in GPIHBP1-/- mice. It is also possible that the deletion of GPIHBP1 causes the alteration of 
LpL localization or LpL function in the arterial wall and, in turn, affects multiple events in 
atherogenesis. Using techniques that have been developed in our laboratory, we will be able to 
demonstrate the direct effects of GPIHBP1 deficiency in arterial LDL uptake and deposition, as 
well as LpL levels and distribution. Moreover, potential regulation of GPIHBP1 in the arterial 
wall by dietary FA can also be determined.  
A question of particular interest is whether the role of SMC-secreted LpL in mediating 
arterial lipid deposition is similar to that of macrophage-secreted LpL.  In ourstudies, we have 
not found strong associations between SMC and LpL in response to dietary FA or the injection 
of heparin. We have not examined SMC-specific LpL mRNA levels in the arterial wall. Note 





increased in proximal artery homogenates. It is possible that SMC-specific LpL expression 
accounts for the increase in LpL transcription in artery homogenates of n-3-fed mice. Therefore, 
we postulated that dietary FA influence arterial LpL transcription and expression in a cell-
specific manner. Therefore, further characterization of the interaction of LpL and aortic SMC 
will provide insights into the mechanism behind the role of cell-specific LpL in mediating 
atherosclerosis. In situ hybridization of LpL mRNA expression in the arterial wall and laser 
capture microdissection for arterial SMC will provide a more definitive answer on gene 
expression levels of LpL in SMC when compared with LpL expression in aortic macrophages.  
LpL serves an important role in anchoring LDL to the arterial wall, as well as deeper 
LDL infiltration into arterial intima. However, monocyte infiltration and differentiation into 
macrophages might co-exist with arterial lipid retention. Both events have been recognized as 
important in early progression of atherosclerosis. Thus, the effects of arterial lipid retention and 
inflammatory responses in initiating atherosclerosis seem difficult to separate. Our studies in 
Chapter 5 indicated that LpL can also act as a macrophage adhesion molecule. LpL deficiency in 
the arterial wall decreased macrophage adhesion and infiltration. In aortic medial layers, 
macrophage content was reduced in MCKL0/L0 mice when compared with MCKL0/Wt mice. 
Collectively, these studies have demonstrated that LpL plays a key role in both lipid retention 
and inflammation pathways providing valuable insights on studying LpL in the early progression 
of atherosclerosis.   
Additional studies would further strengthen understandings on the mechanisms 
underlying regulation of LpL and atherosclerosis by dietary FA. Specific FA have been 
postulated as a potent regulator for many genes that are important in the events related to 





expression of pro-inflammatory markers.  In the current studies, a number of inflammatory 
markers were assessed in the artery when responding to specific FA, including IL-6, IL-10 and 
TNF-α. Additional measurements of markers of inflammation such as transcription factors (eg., 
NF-кB) and other pro- or anti-inflammatory genes (e.g., IL-10 and IL-12) could further define 
the role of n-3 FA in modulating inflammatory response in our models.  
A phenotypic switch in the macrophage population has been reported during 
development of atherosclerosis. As atherosclerotic lesions progress, macrophages exhibit an 
inflammatory phenotype and produce cytokines that are associated with classical activation. 
However, evidence is lacking on the effects of n-3 FA on markers of these alternatively activated 
macrophages. Our preliminary studies on examining arterial alternatively activated mannose 
receptor (MR) showed that specific FA do not affect mRNA and arterial distribution of MR. 
Thus, we hypothesize that dietary n-3 FA regulate the inflammatory responses likely through the 
inhibition of pro-inflammatory marker expression, but not through the activation of anti-
inflammatory markers. Microarray analyses that assess gene expression globally in the artery 
would help to identify potential factors that are influenced by dietary FA in mediating arterial 
inflammatory responses and arterial lipid deposition.  
This thesis work demonstrated the beneficial effects of n-3 FA on atherosclerosis; 
however, these are the effects of combined intakes of EPA and DHA. Most likely, different 
ratios of EPA and DHA to total lipid intake will have different effects in different biological 
events. Several studies have suggested that DHA, in comparison with EPA, is more potent and 
has the greater effects on regulation of gene transcription (Hirafuji et al., 2003). Mechanisms 





genetically modified animal models to provide insights into the disparate effects of n-3 FA on 
cells and tissues.    
In summary, the underlying mechanisms through which LpL modulates arterial lipid 
deposition in the development of atherosclerosis have been investigated. These studies defined 
„novel‟ pathways underlying the potential of n-3 FA to decrease the risk for CVD, in part, 
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